

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/044160 A2

(51) International Patent Classification⁷: C12N

(US). KHARBANDA, Surender [US/US]; 8 Jacqueline Circle, Natick, MA 01760 (US). WEITMAN, Steven, D. [US/US]; 44 Edge Creek Dr., San Antonio, TX 78254 (US).

(21) International Application Number:
PCT/US2003/035848

(22) International Filing Date:
12 November 2003 (12.11.2003)

(74) Agent: HIGHLANDER, Steven, L.; Fulbright & Jaworski, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/293,391 13 November 2002 (13.11.2002) US
10/447,839 29 May 2003 (29.05.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 10/293,391 (CON)
Filed on 13 November 2002 (13.11.2002)
US 10/447,839 (CON)
Filed on 29 May 2003 (29.05.2003)

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*):
DANA-FARBER CANCER INSTITUTE, INC.
[US/US]; 44 Binney Street, Boston, MA 02115 (US).
ILEX PRODUCTS, INC. [US/US]; 4545 Horizon Hill Bld., San Antonio, TX 78229-2263 (US).

Published:
— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KUFFE, Donald, W. [US/US]; 179 Grove Street, Wellesley, MA 02181

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUC1 INTERFERENCE RNA COMPOSITIONS AND METHODS DERIVED THEREFROM

(57) Abstract: The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and increasing the sensitivity of cancer cells to chemotherapeutic agents by downregulating MUC1 expression by interfering RNA.



WO 2004/044160 A2

DESCRIPTION

MUC1 INTERFERENCE RNA COMPOSITIONS AND METHODS DERIVED THEREFROM

5

This application is a continuation-in-part of U.S. Patent Application Serial No. 10/447,839, filed May 29, 2003, which is continuation-in-part of U.S. Patent Application 10/293,391, filed November 13, 2002, each of which are hereby incorporated by reference in their entirety. The United States government may own rights in the present invention pursuant to grant number R21-CA87421 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

10

FIELD OF THE INVENTION

The present invention relates generally to the field of cancer therapy, and more specifically, to the use of modulators or agents that interact with MUC1 as a point on intervention in cancer therapy.

15

BACKGROUND OF THE INVENTION

The human MUC1 mucin glycoprotein is expressed on the apical borders of secretory epithelial cells on the luminal surface of most glandular epithelia (Kufe *et al.*, 1984). In carcinomas, MUC1 is highly overexpressed throughout the entire cell membrane and cytoplasm (Kufe *et al.*, 1984; Perey *et al.*, 1992). As such, the aberrant pattern of MUC1 expression in carcinoma cells may confer a function for MUC1 normally found at the apical membrane to the entire cell membrane. The hallmark of MUC1 mucin is an ectodomain comprising a glycosylated 20 amino acid extracellular sequence that is tandemly repeated 25-100 times in each molecule (Strouss & Decker, 1992). The mucin glycosylation level appears to be lower in cancer cells than normal cells of ductal epithelial tissue (U.S. Patent 5,506,343). This hypoglycosylation results in the exposure of tumor-specific epitopes that are hidden in the fully glycosylated mucin.

25

30

Over ninety percent of breast cancers show an increased expression of MUC1 (also known as Mucin, Epithelial Membrane Antigen, Polymorphic Epithelial Mucin, Human Milk Fat Globule Membrane antigen, Episialin, DF-3, *etc.*; *see* Barry & Sharkey, 1985). Several clinical studies have suggested that mucinous tumor antigens expressed on the cell surface of tumor cells
 5 associate with poor prognosis of a variety of cancer types (Itzkowitz *et al.*, 1990).

MUC1 is expressed as both a transmembrane form and a secreted form (Finn *et al.*; 1995). The repeating sialyl epitopes of MUC1 (the 'ectodomain') are shed into the serum (Reddish *et al.*, 1996). The N-terminal ectodomain (the extracellular domain that is cleaved) of MUC1 consists of a variable number of the 20-amino acid tandem repeats that are subject to O-
 10 glycosylation. This mucin extends far above the cell surface and past the glycocalyx, making it easily available for interactions with other cells. The C-terminal region of MUC1 includes a 37 amino acid transmembrane domain and a 72 amino acid cytoplasmic tail that contains sites for tyrosine phosphorylation. An approximately 45 amino acid extracellular domain remains following cleavage of the ectodomain. It is not known what enzyme is responsible for the
 15 cleavage of the ectodomain at this time. The extracellular domain, or "MUC1/ECD," remaining after cleavage of the ectodomain, typically includes the amino acid sequence:

TINVHDTVETQFNQYKTEAASRYNLTISDVSVSDVPPFSAQSGAG

The cytoplasmic domain of MUC1 ("MUC1/CD") encompasses multiple sub-domains that are important in intracellular signaling in cancer cells. β -Catenin binds directly to MUC1/CD at a SAGNGGSSL motif (Yamamoto *et al.*, 1997). β -Catenin, a component of the adherent junctions of mammalian epithelium, binds to cadherins at the intracellular surface of the plasma membrane and performs a signaling role in the cytoplasm as the penultimate downstream
 20 mediator of the wnt signaling pathway (Takeichi, 1990; Novak & Dedhar, 1999). The ultimate mediator of the wnt pathway is a nuclear complex of β -catenin and lymphoid enhancer factor/T cell factor (Lef/Tcf), which stimulates the transcription of a variety of target genes (*see e.g.*, Molenaar *et al.*, 1996; Brunner *et al.*, 1997). Defects in the β -catenin-Lef/Tcf pathway are involved in the development of several types of cancers (Novak & Dedhar, 1999).

Glycogen synthase kinase β (GSK3 β) also binds directly to MUC1/CD and phosphorylates serine in a DRSPY site adjacent to the β -catenin binding motif, thereby
 30

decreasing the association between MUC1 and β -catenin (Li *et al.*, 1998). In addition, the c-Src tyrosine kinase also binds to and phosphorylates a MUC1/CD SPYEKV motif, resulting in an increased interaction between MUC1/CD and β -catenin and a decreased interaction between MUC1/CD and GSK3 β (Li *et al.*, 2001).

5 MUC1 associates also constitutively with the epidermal growth factor receptor (EGF-R, HER1) at the cell membrane and activated EGF-R induces phosphorylation of the MUC1/CD SPYEKV motif (Li *et al.*, 2001a). EGF-R mediated phosphorylation of MUC1/CD appears to increase the interaction of MUC1 with c-Src and β -catenin and downregulate the interaction between MUC1 and GSK3 β . These results support a model wherein MUC1 integrates the
10 signaling among c-Src, β -catenin and GSK3 β pathways and dysregulation of this integrated signaling by aberrant overexpression of MUC1 in cancer cells could promote the transformed phenotype (Li *et al.*, 2001a).

The Armadillo protein p120^{ctn} also binds directly to MUC1/CD resulting in the nuclear localization of p120 (Li & Kufe, 2001). P120 has been implicated in cell transformation and
15 altered patterns of p120 expression have been observed in carcinomas (*see e.g.*, Jawhari *et al.*, 1999; Shimazui *et al.*, 1996). P120 is a v-Src tyrosine kinase substrate, binds to E-cadherin, and is implicated as a transcriptional coactivator (Reynolds *et al.*, 1989; Reynolds *et al.*, 1994; Daniels & Reynolds, 1999). The observations that p120 localizes to both cell junctions and the
nucleus has supported a role for p120, like β -catenin, in the regulation of both cell adhesion and
20 gene transcription. Decreased cell adhesion resulting from association of MUC1 and p120 may be involved in increased metastatic potential of MUC1-expressing tumor cells.

Thus, the available evidence indicates that MUC1/CD functions to transfer signals from the extracellular domain to the nucleus, and utilizes signaling mechanisms that have been implicated in adhesion receptor and growth factor signaling and cellular transformation. It is
25 therefore desirable to identify compositions and methods related to modulation of the MUC1-mediated signaling and its putative role in cellular transformation.

SUMMARY OF THE INVENTION

The present invention encompasses methods of use and pharmaceutical compositions relating to the discovery that the extracellular domain of MUC1 provides binding domains for endogenous ligands and that such binding is related to an oncogenic function of MUC1 and the proliferation of cancer cells.

Broadly, the invention relates to cancer treatment compositions and methods employing agents or treatment methodologies that comprise or include antagonists of MUC1 modulated cell proliferation. Preferred are methods and compositions that comprise agents that bind to MUC1/ECD, bind to MUC1/ECD ligands that activate the oncogenic function of MUC1, or downregulate the expression of MUC1.

Thus, one aspect of the present invention provides for a method for inhibiting the proliferation of cancer cells, comprising administration of an effective amount of a MUC1/ECD antagonist. MUC1/ECD antagonists are agents that downregulate or reduce the quantity of MUC1/ECD presented on cell surfaces, or downregulate the level of wild-type MUC1/ECD ligands available for binding to MUC1/ECD, and/or MUC1/ECD binding inhibitors. A “MUC1/ECD binding inhibitor” means a compound that inhibits the binding of MUC1 wild-type ligands, which may suitably include neuregulin 2 isoform 5 (SEQ ID NO: 2), neuregulin 2 isoform 6 (SEQ ID NO: 3), and appropriate fragments thereof, to MUC1/ECD or a compound that inhibits the binding of an antibody that binds to an epitope within SEQ ID NO: 4 to MUC1/ECD. Appropriate fragments of neuregulin 2 isoform 5 (SEQ ID NO: 2) and neuregulin 2 isoform 6 (SEQ ID NO: 3) are those that bind to MUC1/ECD. MUC1/ECD binding inhibitors include antibodies, polypeptides and small molecules that inhibit such binding. A “MUC1/ECD-P1 binding inhibitor” means a MUC1/ECD binding inhibitor identified by inhibition of the binding to MUC1/ECD of an antibody the binds to an epitope within SEQ ID NO: 4.

In one embodiment of the invention, the MUC1/ECD inhibitor is the polypeptide of SEQ ID NO: 1, or a fragment comprising at least four consecutive amino acids of SEQ ID NO: 1 such as TINV, NVHD, VHDV, DVET, VETQ, ETQF, TQFN, QFNQ, FNQY, NQYK, QYKT, YKTE, KTEA, TEAA, EAAS, AASR, ASRY, SRYN, RYNL, YNLT, NLTI, LTIS, TISD, ISDV, SDVS, DVSV, VSVS, SVSD, VSDV, SDVP, DVPF, VPFP, PFPP, PFPS, PFSA, FSAQ, SAQS, AQSG, QSGA, and SGAG. In other embodiments, the MUC1/ECD inhibitor is a

conservative variant of the foregoing peptides. In another embodiment, the MUC1/ECD binding inhibitor is the polypeptide of SEQ ID NO: 4, SEQ ID NO: 5, or conservative variants thereof.

In another embodiment of the present invention, the MUC1/ECD inhibitor is an antibody that binds to one or more epitopes in the MUC1/ECD sequence SEQ ID NO: 1. In other
5 embodiments of the invention, the MUC1/ECD inhibitor is an antibody that binds to an epitope within SEQ ID NO: 2 or SEQ ID NO: 3. The antibody may be a polyclonal or a monoclonal antibody. Monoclonal antibodies may be humanized or human monoclonal antibodies. It may also be a bispecific antibody or a fragment which comprises an antigen binding region. In some
10 embodiments, the antibody is conjugated to a chemotherapeutic agent, radioisotope, toxin, or an effector that induces a cytolytic or cytotoxic immune response. Such conjugates may comprise a cytokine, an antimetabolite, an anthracycline, a vinca alkaloid, an antibiotic, an alkylating agent, a naturally-derived toxin, or an Fc region of a IgG1 immunoglobulin.

In another embodiment, the method further comprises the administration of a chemotherapeutic agent or radiation in combination with a MUC1/ECD antagonist.
15 Chemotherapeutic agents typically include alkylating agents, topoisomerase inhibitors, antimetabolites, tubulin interactive agents, anti-hormonal agents, ornithine decarboxylase inhibitors and tyrosine kinase inhibitors.

In various embodiments, the cancer cells are selected from the group consisting of skin cancer cells, prostate cancer cells, lung cancer cells, brain cancer cells, breast cancer cells,
20 ovarian cancer cells, cervical cancer cells, liver cancer cells, pancreatic cancer cells, colon cancer cells, stomach cancer cells and leukemia cells.

Another aspect of the invention is a method for reducing tumor growth in a mammal comprising administration of a therapeutic amount of a chemotherapeutic agent or radiation and an effective amount of a MUC1/ECD antagonist. In a preferred embodiment, the mammal is
25 human. In one embodiment, the method is for treating refractory tumors comprising administration of a therapeutic amount of a chemotherapeutic agent or radiation and an effective amount of a MUC1/ECD antagonist subsequent to treatment with one or more chemotherapeutic agents. In various embodiments, the tumor is a tumor of the skin, prostate, lung, brain, breast, ovary, cervix, liver, pancreas, colon, stomach or hematopoietic system.

30 Other aspects of the invention relate to pharmaceutical compositions comprising MUC1/ECD antagonists and a pharmaceutically acceptable carrier. Wherein the antagonist is a

MUC1/ECD binding inhibitor that may be the polypeptide of SEQ ID NO: 1 or a fragment comprising at least four consecutive amino acids, or conservative variants thereof, and a pharmaceutically acceptable carrier. In some embodiments, the MUC1/ECD inhibitor may be the polypeptide of SEQ ID NO: 4, SEQ ID NO: 5, or conservative variants thereof. In other
5 embodiments, the pharmaceutical composition comprises an antibody that is a MUC1/ECD binding inhibitor and binds to an epitope within sequences of the peptides selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and a pharmaceutically acceptable carrier.

The present invention also encompasses methods for screening MUC1/ECD binding
10 inhibitor activity. One embodiment comprises a method of identifying a compound that inhibits the binding of ligands to MUC1/ECD, the method comprising: (a) providing a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO: 5; (b) contacting said polypeptide with a test compound and a ligand to the extracellular domain of MUC1 selected from the group consisting of antibodies to MUC1/ECD that stimulate MUC1 mediated cancer cell proliferation and wild-
15 type ligands that bind to MUC1/ECD and stimulate cancer cell proliferation; and (c) determining whether the binding of said antibody to MUC1/ECD or wild type ligand is decreased relative to an appropriate control. Appropriate controls include, but are not limited to, assays wherein test compounds are excluded. In one embodiment, the MUC1/ECD antibody that stimulates MUC1 mediated cancer cell proliferation is an antibody that binds to an epitope within SEQ ID NO: 4.
20 In other embodiments, the wild-type ligands may suitable include neuregulin 2 isoform 5 (SEQ ID NO: 2) and appropriate fragments thereof and neuregulin 2 isoform 6 (SEQ ID NO: 3) and appropriate fragments thereof, wherein appropriate fragments are those that bind to the SEQ ID NO: 1 and have suitable growth stimulatory activity.

Another embodiment is a method of identifying a compound that inhibits the proliferation
25 of MUC1-expressing cancer cells, the method comprising: (a) providing a population of MUC1-expressing cancer cells; (b) contacting said population of MUC1-expressing cancer cells with a test compound and a ligand to the extracellular domain of MUC1 selected from the group consisting of antibodies to MUC1/ECD that stimulate MUC1 mediated cancer cell proliferation and wild-type ligands that bind to MUC1/ECD and stimulate cancer cell proliferation; and (c)
30 determining whether the proliferation of the population of MUC1-expressing cancer cells is decreased by comparison to an appropriate control. Appropriate controls include, but are not

limited to, proliferation assays wherein test compounds are excluded. In one embodiment, the MUC1/ECD antibody that stimulates MUC1 mediated cancer cell proliferation is an antibody that binds to an epitope within SEQ ID NO: 4. In other embodiments, the wild type ligands may suitable include neuregulin 2 isoform 5 (SEQ ID NO: 2) and appropriate fragments thereof and
5 neuregulin 2 isoform 6 (SEQ ID NO: 3) and appropriate fragments thereof, wherein appropriate fragments are those that bind to the SEQ ID NO: 1 and have suitable growth stimulatory activity.

The present invention also provides methods for identifying compounds that downregulate MUC1/ECD expression. The method comprises: (a) providing a population of MUC1-expressing cancer cells; (b) contacting said population of MUC1-expressing cancer cells
10 with a test compound; (c) utilizing an anti-MUC1/ECD antibody to identify polypeptides comprising MUC1/ECD in the MUC1-expressing cancer cells; and (d) determining whether the expression of polypeptides comprising MUC1/ECD is decreased in comparison to controls wherein the test compound was excluded.

The present invention also encompasses pharmaceutical compositions comprising
15 compounds identified by the foregoing methods and a pharmaceutically acceptable carrier.

Further aspects of the present invention provide for interfering RNA compositions that can downregulate MUC1 expression and methods of use of such compositions. One aspect provides for a double-stranded RNA complex comprising a first RNA sequence of 19 to 23
20 nucleotides that will hybridize to SEQ ID NO: 19 under stringent conditions, or in a preferred embodiment will hybridize to SEQ ID NO: 20 under stringent conditions, and a second RNA sequence of 19 to 23 nucleotides that will hybridize to the first RNA under stringent conditions. The first and second RNA sequences may be separate RNA oligonucleotides or may be two portions of a single RNA oligonucleotide. In some embodiments, the double-stranded RNA complex may comprise at least one modified internucleoside linkage and/or at least one modified
25 sugar moiety.

Another aspect of the invention provides for a 5' phosphorylated RNA oligonucleotide of 29 to 40 bases that will hybridize under stringent conditions to SEQ ID NO: 19, or in a preferred
30 embodiment will hybridize to SEQ ID NO: 20. In various embodiments, the 5' phosphorylated RNA oligonucleotide of may comprise at least one modified internucleoside linkage and/or at least one modified sugar moiety.

The present invention also provides for a method of inhibiting the expression of MUC1, comprising contacting a cell that expresses MUC1 with an interfering RNA oligonucleotide, that will hybridize with SEQ ID NO: 19 under stringent conditions, or in a preferred embodiment, will hybridize with SEQ ID NO: 20 under stringent conditions. In some embodiments, the
5 interfering RNA oligonucleotide is a first RNA sequence of 19 to 23 nucleotides of a double-stranded RNA complex comprising a second RNA sequence of 19 to 23 nucleotides, wherein the first RNA sequence will hybridize to the second RNA sequence under stringent conditions. The first and second RNA sequences may be separate RNA oligonucleotides or they may be two portions of a single RNA oligonucleotide. The double-stranded RNA complex may comprise at
10 least one modified internucleoside linkage and/or at least one modified sugar moiety. In other embodiments, the interfering RNA oligonucleotide is a 5' phosphorylated RNA oligonucleotide of 29 to 40 bases that may comprise at least one modified internucleoside linkage and/or at least one modified sugar moiety. In some embodiments, the MUC1 expressing cell is a cancer cell which in various embodiments may be a skin cancer cell, a prostate cancer cell, a lung cancer
15 cell, a brain cancer cell, a breast cancer cell, an ovarian cancer cell, a cervical cancer cell, a liver cancer cell, a pancreatic cancer cell, a colon cancer cell, a stomach cancer cell or a leukemia cell.

Another aspect of the invention is a method of inhibiting the proliferation of a cancer cell that expresses MUC1 comprising contacting the cancer cell with an interfering RNA oligonucleotide, that will hybridize with SEQ ID NO: 19 under stringent conditions, or in a
20 preferred embodiment, will hybridize with SEQ ID NO: 20 under stringent conditions. In some embodiments, the interfering RNA oligonucleotide is a first RNA sequence of 19 to 23 nucleotides of a double-stranded RNA complex comprising a second RNA sequence of 19 to 23 nucleotides, wherein the first RNA sequence will hybridize to the second RNA sequence under stringent conditions. The first and second RNA sequences may be separate RNA
25 oligonucleotides or they may be two portions of a single RNA oligonucleotide. The double-stranded RNA complex may comprise at least one modified internucleoside linkage and/or at least one modified sugar moiety. In other embodiments, the interfering RNA oligonucleotide is a 5' phosphorylated RNA oligonucleotide of 29 to 40 bases that may comprise at least one modified internucleoside linkage and/or at least one modified sugar moiety. In various
30 embodiments, the cancer cell is a skin cancer cell, a prostate cancer cell, a lung cancer cell, a

brain cancer cell, a breast cancer cell, an ovarian cancer cell, a cervical cancer cell, a liver cancer cell, a pancreatic cancer cell, a colon cancer cell, a stomach cancer cell or a leukemia cell.

The present invention further provides for an interfering RNA composition comprising an RNA oligonucleotide of about 17 to about 50 bases that can inhibit the expression of MUC1 when administered to the cell in an effective amount.

Further aspects of the present invention provide for methods of inhibiting the expression MUC1 in a cell, which may be a cancer cell, comprising administering an interfering RNA oligonucleotide of about 17 to about 50 bases in length in an amount effective to inhibit the expression of MUC1. Also provided are methods of inhibiting the proliferation of a MUC1 expressing cancer cell, comprising administering an interfering RNA oligonucleotide of about 17 to about 50 bases in length in an amount effective to inhibit the proliferation of the cancer cell.

The present invention also encompasses pharmaceutical compositions comprising interfering RNA of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1: Effect of anti-MUC1-P1 antibody on proliferation of ZR-75-1 breast carcinoma cells.

FIG. 2: Effect of anti-MUC1-P1 antibody on proliferation of SW480 cells stably expressing an empty vector (SW480/V) or MUC1 (SW480/MUC1).

FIG. 3: Effect of ZR-75-1 conditioned medium on proliferation of SW480 cells stably expressing an empty vector (SW480/V) or MUC1 (SW480/MUC1).

FIG. 4: Effect of MUC1 on H₂O₂ and taxol-induced apoptosis in HeLa cells stably expressing an empty vector (HeLa/V) or MUC1 (HeLa/Muc1). The results are expressed as the percentage apoptosis (mean±SE) of three separate experiments.

FIGS. 5A-D: Effect of anti-MUC1 siRNAs #1 and #2. FIGS. 5A and 5B show the decrease in MUC1 protein expression elicited by siRNAs as shown by Western blot analysis in

A549 and MCF-7 cells respectively. FIGS. 5C and 5D show the decrease in MUC1 RNA elicited by siRNAs as shown by RT-PCR immunoblot in A549 and MCF-7 cells respectively.

FIG. 6: Effect of anti-MUC1 siRNAs #3, #4 and #5 on MUC1 protein expression in MCF-7 cells as shown by immunoblot.

5 **FIG. 7:** Effect on apoptosis in A549 cells of the combination of transfection of siRNA #2 plus treatment with cisplatinum (CDDP).

FIG. 8: Effect on proliferation in A549 cells of the combination of transfection of siRNA #1 or siRNA #2 or plus treatment with cisplatinum (CDDP).

FIG. 9: Depiction of plasmid (pU6-MUC1siRNA#2) that expresses siRNA #2.

10 **FIG. 10:** Binding of antibody IPB-01 to immobilized MUC1-Yex-mFc.

FIG. 11: Binding of antibody IPB-02 to immobilized MUC1-Yex-mFc.

FIG. 12: Summary of data showing that MUC1 confers resistance to CDDP *in vivo*. ZR-75-1/vector cells (○, ●) or ZR-75-1/MUC1siRNA (□, ■) cells (1×10^7) were injected into nude mice that had been pretreated with β -estradiol. The mice were treated as indicated (arrows) with intraperitoneal injections of PBS (□, ○) or 7 mg/Kg CDDP (●, ■). The results are expressed as the tumor volume (mean \pm S.D. of 4-8 mice per group).

DETAILED DESCRIPTION OF THE INVENTION

20 I. Polypeptides

The polypeptides of the present invention can be created by synthetic techniques or recombinant techniques which employ genomic or cDNA cloning methods. Polypeptides can be routinely synthesized using solid phase or solution phase peptide synthesis. Methods of preparing relatively short polypeptides peptides, such as P0 (SEQ ID NO: 9), P1
25 (SEQ ID NO: 4), P2 (SEQ ID NO: 6) and P3 (SEQ ID NO: 7), by chemical synthesis are well known in the art. Such polypeptides could, for example be produced by solid-phase peptide synthesis techniques using commercially available equipment and reagents such as those available from Milligen (Bedford, Mass.) or Applied Biosystems-Perkin Elmer (Foster City, CA). Alternatively, segments of such polypeptides could be prepared by solid-phase synthesis
30 and linked together using segment condensation methods such as those described by Dawson *et al.* (1994). During chemical synthesis of such polypeptides, substitution of any amino acid is

achieved simply by replacement of the residue that is to be substituted with a different amino acid monomer.

Wild-type MUC1/ECD ligand polypeptides can be identified as exemplified in Example 3 herein. Recombinant MUC1/ECD ligands can then be prepared by methods known in the art.

5 The polypeptides of the present invention include variant polypeptides. By "variant" polypeptide is intended a polypeptide sequence modified by deletion or addition of one or more amino acids at one or more sites in the sequence; or substitution of one or more amino acids at one or more sites within the sequence. Variant polypeptides encompassed by the present invention retain the desired biological activity of the polypeptide from which they are derived.
10 Such variants will have at least 40%, 50%, 60%, 70%, generally at least 75%, 80%, 85%, preferably about 90% to 95% or more, and more preferably about 98% or more sequence identity to the amino acid sequence of the polypeptide from which they are derived. The percentage of sequence identity, also termed homology, between a polypeptide native and a variant sequence may be determined by comparing the two sequences using the Gap program (Wisconsin
15 Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wisconsin), which uses the algorithm of Smith and Waterman, (1981).

 The polypeptides of the present invention also include variant polypeptides with one or more conservative substitutions. For the purposes of classifying amino acid substitutions as conservative, amino acids are grouped as follows: Group I (hydrophobic sidechains): norleucine,
20 met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gin, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class.

 Also encompassed by the present invention are chemical derivatives of polypeptides.
25 "Chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized residues include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, *p*-toluene sulfonyl groups, carbobenzoxy groups, *t*-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts,
30 methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be

derivatized to form O-acyl or O-alkyl derivatives. The imadazole group of histidine may be derivatized to form N-imbenzylhistidine.

The term "polypeptide" as used herein indicates a molecular chain of amino acids and does not refer to a specific length of the product.

5

II. Antibodies

The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (*e.g.*, bispecific antibodies), and antibody fragments, so long as they exhibit the
10 desired biological activity.

Methods for generating polyclonal antibodies are well known in the art. Briefly, a polyclonal antibody is prepared by immunizing an animal with an antigenic composition and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera including rabbit, mouse, rat, hamster, guinea pig and goat.

15

As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for
20 conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine. As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete Freund's
25 adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

25

The serum for an immunized animal may be used as is for various applications or the desired antibody fraction may be purified by well-known methods, such as affinity chromatography using another antibody or a peptide bound to a solid matrix.

30

Monoclonal antibodies (MAbs) may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference.

Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified expressed polypeptide. The immunizing composition is administered in a manner that effectively stimulates antibody producing cells.

5 The methods for generating monoclonal antibodies (MAbs) generally begin along the same lines as those for preparing polyclonal antibodies. The use of rats may provide certain advantages (Goding, 1986), but mice are preferred, with the BALB/c mouse being the most routinely used and generally gives a higher percentage of stable fusions.

10 Following immunization, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred. Often, a panel of animals will have been immunized and the spleen of animal with the highest antibody titer will be removed and obtaining lymphocytes from the spleen.

15 The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and have enzyme deficiencies that render them incapable of growing in certain selective media that support the growth of only the desired fused cells (hybridomas). Selected hybridomas are serially diluted
20 and cloned into individual antibody-producing cell lines, which can then be propagated indefinitely to provide MAbs.

In accordance with the present invention, fragments of the monoclonal antibody of the invention can be obtained from the monoclonal antibody produced as described above, by methods which include digestion with enzymes such as pepsin or papain and/or cleavage of
25 disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated synthesizer, or by expression of full-length gene or of gene fragments in *E. coli* or other recombinant microorganisms and cell lines.

30 The present invention also encompasses various antibody conjugates. Conjugates with fluorescein markers are prepared by methods known in the art, such as conjugation in the presence of coupling agents or by reaction with an isothiocyanate. Conjugates with metal

chelates are similarly produced. Other moieties to which antibodies may be conjugated include radionuclides such as ^{131}I , ^{90}Y , ^{105}Rh , ^{47}Sc , ^{67}Cu , ^{212}Bi , ^{211}At , ^{188}Re , ^{109}Pd , ^{47}Sc , ^{212}Pb , and ^{153}Sm and the like, as described in Gansow (1991), which is herein incorporated by reference.

Monoclonal antibodies of the invention can also be coupled to conventional
5 chemotherapeutic agents such as an antimetabolite, an anthracycline, a vinca alkaloid, an antibiotic or an alkylating agent. Drugs that may be coupled to the antibodies for targeting include compounds such as doxorubicin, cyclophosphamide, cisplatin, adriamycin, estramustine, fluorouracil, ethinyl estradiol, mitoxantrone, methotrexate, finasteride, taxol, and megestrol. Methods of coupling may be direct via covalent bonds, or indirect via linking molecules, and will
10 generally be known in the art for the particular drug selected and are made using a variety of bifunctional protein coupling agents. Examples of such reagents are SPDP, IT, bifunctional derivatives of imidoesters such as dimethyl adipimidate HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bisazido compounds such as bis-(R-azidobenzoyl) hexanediamine, bisdiazonium derivatives such as bis-(R-diazoniumbenzoyl)ethylenediamine,
15 diisocyanates such as tolylene 2,6-diisocyanate, and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene (*see, e.g., Thorpe et al., 1982, herein incorporated by reference*).

The antibodies of the present invention may also be conjugated with various toxin molecules or an effector such as IgG1 immunoglobulin, which induces cytolytic or cytotoxic immune response. Thus, the two components may be chemically bonded together by any of a
20 variety of well-known chemical procedures. For example, the linkage may be by way of heterobifunctional cross-linkers, e.g. SPDP, carbodiimide, glutaraldehyde, or the like. The toxin molecules may also be fused to the antibody or binding regions thereof by recombinant means, such as through the production of single chain antibodies. The genes encoding protein chains may be cloned in cDNA or in genomic form by any cloning procedure known to those skilled in
25 the art (*see, e.g., Sambrook et al., 1989*). The recombinant production of various immunotoxins is well-known within the art and can be found, for example in Thorpe *et al.* (1982a), Waldmann (1991), and Pastan *et al.* (1992), all herein incorporated by reference. A variety of toxin molecules are suitable for use as the cytotoxic domain in the antibody conjugates or fusion proteins described here. Any toxin known to be useful as the toxic component of an
30 immunotoxin may be used, preferably a protein toxin that may be recombinantly expressed. Particularly useful as the cytotoxic domain are bacterial toxins such as *Pseudomonas* exotoxin A

(PE), diphtheria toxin, shiga toxin and shiga-like toxin, and ribosome inactivating toxins derived from plants and fungi, including ricin, α -sarcin, restrictotocin, mitogellin, tricanthosin, saporin-G, saporin-1, momordin, gelonin, pokeweed antiviral protein, abrin, modeccin and others described in Genetically Engineered Toxins, ed. A. Frankel, Marcel Dekker, Inc. (1992), herein incorporated by reference, and any recombinant derivatives of those proteins (*see* Olsnes 1981; U.S. Patent 4,675,382; and U.S. Patent 4,894,443, herein incorporated by reference).

The antibody may also be a bispecific antibody which recognizes both the MUC1/ECD and an antigen which promotes the release of a cytokine such as IL-1, TNF alpha and CD16, CD2, CD3 L.C. CD28, which in turn, will activate the release of IFN γ or TNF α , respectively.

The MAb's of the present invention encompass chimeric Mabs, including, "humanized" forms of non-human (*e.g.*, murine) Mabs. Humanized MABs are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (*see* Jones *et al.*, 1986; Riechmann *et al.*, 1988; and Presta, 1992). Fully human MABs are preferred in the therapeutic methods of the present invention.

"Single-chain FV" or "sFv" antibody fragments of the present invention comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding (*see* Pluckthun, 1994).

III. Screening and Diagnostic Assays

The present invention provides for methods for identifying compounds that inhibit the binding of various ligands to MUC1/ECD. The binding ligands include neuregulin 2 isoform 5 (SEQ ID NO: 2), neuregulin 2 isoform 6 (SEQ ID NO: 3) and fragments of either isoform that bind to MUC1/ECD and, in a preferred embodiment, an antibody that binds to an epitope within SEQ ID NO: 4.

In one embodiment, the screening method utilizes an *in vitro* competitive binding assay, wherein the capacity of a test compound to inhibit the binding of the aforementioned ligands to a polypeptide comprising SEQ ID NO:1 or SEQ ID NO: 5 is assessed. In such an assay, the polypeptide comprising MUC1/ECD derived sequences SEQ ID NO: 1 or SEQ ID NO: 5 may be conjugated to another protein or produced as a fusion protein, *e.g.*, the GST-MUC1/ECD fusion protein exemplified herein in Example 3. Other suitable conjugates and fusion proteins may be made by one of skill in the art utilizing procedures known in the art. The polypeptides or MUC1/ECD ligands may be labeled with a radioisotope or fluorescent label (*e.g.*, phycobiliproteins, such as phycoerythrin and allophycocyanins, fluorescein and Texas red). Alternatively an enzyme, such as peroxidase, may be used and conjugated either directly or indirectly via a biotin and avidin or streptavidin system. Decreased binding upon introduction of a test compound is indicative of competitive binding.

A compound that inhibits the binding of ligands to MUC1/ECD may be a modulator, that is an antagonist or agonist of the biological activity initiated by MUC1/ECD binding by neuregulin 2 isoforms 5 or 6. *E.g.*, the antibody raised to polypeptide P1 (SEQ ID NO: 4) is expected to inhibit binding of the wild-type ligands but acts as an agonist for the MUC1/ECD binding site, *i.e.*, it stimulates proliferation of carcinoma cells. In contrast, appropriate compounds, such as the MUC1/ECD polypeptide SEQ ID NO: 1, will bind to the endogenous wild-type ligands thereby preventing binding to MUC1/ECD and consequently acting as an antagonist, *i.e.*, preventing or decreasing the proliferation of carcinoma cells that would be otherwise observed upon binding of the MUC1/ECD ligands.

An alternative screening assay can discriminate between MUC1/ECD binding inhibitors that exhibit antagonist and agonist activity in regard to the proliferation of MUC1-expressing cancer cells. The method requires a population of MUC1-positive cancer cells, preferably human

cancer cells. This could be a population of cells that constitutively expresses MUC1, but the population is preferably of a cell type engineered to express MUC1. The latter are more versatile in regard to providing cells for appropriate controls, *e.g.*, cells engineered with an empty vector, and also for enabling the construction of cells expressing MUC1 mutants. Examples of engineered MUC1 cancer cells include, but are not limited to, SW480 and HCT116 colon cancer cells as exemplified in Examples 2 and 4 herein. Inhibition of MUC1/ECD ligand-induced cell proliferation will indicate a test compound with antagonist activity. Controls may comprise incubation of cancer cells engineered with an empty vector (*i.e.*, MUC1-negative) or incubation of MUC1-positive cells in the absence of either the test compound or the MUC1/ECD ligand. One of the latter controls will identify agonists, *i.e.*, stimulation of cancer cell proliferation observed in incubations in which the test compound is present and the MUC1/ECD ligand is absent. Specificity of the agonist activity is established by use of engineered MUC1-negative cells.

Yet another screening assay monitors MUC1/ECD ligand induced phosphorylation of the intracellular domain of MUC1. Alternate screening methodologies employ monitoring of MUC1/ECD ligand induced association of MUC1 with EGF-R, s-Src, β -catenin, GSK3 β or p120. Methods for monitoring such phosphorylation and protein associations are described in Li *et al.* (1998), Li *et al.* (2001), Li *et al.* (2001a) and Li & Kufe (2001), all herein incorporated by reference.

The present invention also provides for methods for identifying compounds that downregulate the expression of MUC1/ECD. In some embodiments of the invention, labeled antibodies to MUC1/ECD are utilized to visualize the expression of MUC/ECD in appropriate cell lines by flow cytometry or by immunohistochemistry, using methods known in the art. Alternatively, the expression of MUC1 can be estimated by immunoblotting or by probing total cellular RNA with labeled DNA probes, *e.g.*, as described in Example 7 herein.

Estimation of the expression of MUC1/ECD can also be used for diagnostic methodologies, wherein antibodies to MUC1/ECD are utilized to investigate the expression of MUC1/ECD on or in cells derived from a subject. Such antibodies can also be utilized for imaging of cancer cells within a subject. Imaging is performed by labeling the anti-MUC1/ECD antibody, *e.g.*, with a radiolabel, and injecting the antibody to a subject and monitoring the location of the antibody within the body of said subject.

IV. Combination with Chemotherapeutic Agents

The present invention encompasses the use of the MUC1/ECD antagonists and agents that downregulate the expression of MUC1, *e.g.*, MUC1 antisense, RNAi and small molecules, in combination with chemotherapeutic agents. While not being limited by any particular theory, MUC1 inhibits the apoptotic response to genotoxic stress induced by certain chemotherapeutic agents, and thereby induces resistance to such agents. MUC1/ECD antagonists and agents that downregulate the expression of MUC1, may be used to mitigate this MUC1 mediated response to chemotherapeutic agents, thereby enhancing the effectiveness of such agents. In this regard, MUC1/ECD antagonists and agents that downregulate the expression of MUC1 will be useful for the treatment cancer cells resistant to chemotherapeutic agents, including residual cancers remaining or reoccurring after cancer chemotherapy. The foregoing rational also pertains to the combination of MUC1/ECD antagonists or agents that downregulate the expression of MUC1 and ionizing radiation.

The chemotherapeutic agents useful in the methods of the invention include the full spectrum of compositions and compounds which are known to be active in killing and/or inhibiting the growth of cancer cells. The chemotherapeutic agents, grouped by mechanism of action include DNA-interactive agents, antimetabolites, tubulin interactive agents, anti-hormonals, anti-virals, ODC inhibitors and other cytotoxics such as hydroxy-urea. Any of these agents are suitable for use in the methods of the present invention.

DNA-interactive agents include the alkylating agents, *e.g.*, cisplatin, cyclophosphamide, altretamine; the DNA strand-breakage agents, such as bleomycin; the intercalating topoisomerase II inhibitors, *e.g.*, dactinomycin and doxorubicin; the nonintercalating topoisomerase II inhibitors such as, etoposide and teniposide; and the DNA minor groove binder plicamycin.

The alkylating agents form covalent chemical adducts with cellular DNA, RNA and protein molecules and with smaller amino acids, glutathione and similar chemicals. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and the role of these alkylating agents in cancer therapy is not well understood. Typical alkylating agents include: nitrogen mustards, such as chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, uracil mustard; aziridine such as thiotepa;

methanesulphonate esters such as busulfan; nitroso ureas, such as carmustine, lomustine, streptozocin; platinum complexes such as cisplatin, carboplatin; bioreductive alkylators, such as mitomycin and procarbazine, dacarbazine and altretamine; DNA strand-breaking agents including bleomycin.

5 Topoisomerases are ubiquitous cellular enzymes which initiate transient DNA strand breaks during replication to allow for free rotation of the strands. The functionality of these enzymes is critical to the replication process of DNA. Without them, the torsional strain in the DNA helix prohibits free rotation, the DNA strands are unable to separate properly, and the cell eventually dies without dividing. Topo I links to the 3'-terminus of a DNA single strand break, 10 while Topo II links to the 5'-terminus of a double strand DNA break. DNA topoisomerase II inhibitors include the following: intercalators such as amsacrine, dactinomycin, daunorubicin, doxorubicin, idarubicin and mitoxantrone; nonintercalators such as etoposide and teniposide; camptothecins including irinotecan (CPT-II) and topotecan. A representative DNA minor groove binder is plicamycin.

15 The antimetabolites generally exert cytotoxic activity by interfering with the production of nucleic acids by one or the other of two major mechanisms. Some of the drugs inhibit production of the deoxyribonucleoside triphosphates that are the immediate precursors of DNA synthesis, thus inhibiting DNA replication. Some of the compounds are sufficiently like purines or pyrimidines to be able to substitute for them in the anabolic nucleotide pathways. These 20 analogs can then be substituted into the DNA and RNA instead of their normal counterparts. The antimetabolites useful herein include: folate antagonists such as methotrexate and trimetrexate; pyrimidine antagonists such as fluorouracil, fluorodeoxyuridine, azacitidine, cytarabine, and floxuridine; purine antagonists include mercaptopurine, 6-thioguanine, fludarabine, pentostatin; sugar modified analogs include cytarabine, fludarabine; ribonucleotide reductase inhibitors 25 include hydroxyurea.

 Tubulin interactive agents interfere with cell division by binding to specific sites on Tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical cell structure units. When the interactive agents bind on the protein, the cell cannot properly form microtubules. Tubulin interactive agents include vincristine and vinblastine, both alkaloids and 30 the taxanes (paclitaxel and docetaxel).

Although their mechanisms of action are different, both taxanes and vinca alkaloids exert their biological effects on the cell microtubules. Taxanes act to promote the polymerization of tubulin, a protein subunit of spindle microtubules. The end result is the inhibition of depolymerization of the microtubules, which causes the formation of stable and nonfunctional microtubules. This disrupts the dynamic equilibrium within the microtubule system, and arrests the cell cycle in the late G₂ and M phases, which inhibits cell replication.

Like taxanes, vinca alkaloids also act to affect the microtubule system within the cells. In contrast to taxanes, vinca alkaloids bind to tubulin and inhibit or prevent the polymerization of tubulin subunits into microtubules. Vinca alkaloids also induce the depolymerization of microtubules, which inhibits microtubule assembly and mediates cellular metaphase arrest. Vinca alkaloids also exert effects on nucleic acid and protein synthesis; amino acid, cyclic AMP, and glutathione synthesis; cellular respiration; and exert immunosuppressive activity at higher concentrations.

Antihormonal agents exert cytotoxic activity by blocking hormone action at the end-receptor organ. Several different types of neoplasm require hormonal stimulation to propagate cell reproduction. The antihormonal agents, by blocking hormone action, deprive the neoplastic cells of a necessary stimulus to reproduce. As the cells reach the end of their life cycle, they die normally, without dividing and producing additional malignant cells. Antihormonal agents are typically derived from natural sources and include: estrogens, conjugated estrogens and ethinyl estradiol and diethylstilbesterol, chlortrianisen and idenestrol; progestins such as hydroxyprogesterone caproate, medroxyprogesterone, and megestrol; androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone.

Adrenal corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti-inflammatory benefits as well as the ability of some to inhibit mitotic divisions and to halt DNA synthesis. these compounds include prednisone, dexamethasone, methylprednisolone, and prednisolone.

Leutinizing-releasing hormone agents or gonadotropin-releasing hormone antagonists are used primarily in the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate. They prevent the biosynthesis of steroids in the testes.

Anti-hormonal agents include antiestrogenic agents such as tamoxifen, antiandrogen agents such as flutamide, and antiadrenal agents such as mitotane and aminoglutethimide.

ODC (or ornithine decarboxylase) inhibitors inhibit cancerous and pre-cancerous cell proliferation by depleting or otherwise interfering with the activity of ODC, the rate limiting enzyme of polyamine biosynthesis important to neoplastic cell growth. In particular, polyamine biosynthesis wherein ornithine is converted to the polyamine, putrescine, with putrescine being subsequently by converted to spermidine and spermine appears to be an essential biochemical event in the proliferation of neoplastic growth in a variety of cancers and cancer cell lines and the inhibition of ODC activity or depletion of ODC in such neoplastic cells has been shown to reduce polyamine levels in such cells leading to cell growth arrest; more differentiated cell morphology and even cellular senescence and death. In this regard, ODC or polyamine synthesis inhibitors are considered to be more cytotoxic agents functioning to prevent cancer reoccurrence or the conversion of pre-cancerous cells to cancerous cells than cytotoxic or cell killing agents. A suitable ODC inhibitor is eflornithine or α -difluoromethyl-ornithine, an orally available, irreversible ODC inhibitor, as well as a variety of polyamine analogs which are in various stages of pre-clinical and clinical research.

Other cytotoxics include agents which interfere or block various cellular processes essential for maintenance of cellular functions or cell mitosis as well as agents which promote apoptosis. In this regard, hydroxyurea appears to act via inhibitors of the enzyme ribonucleotide reductase whereas asparaginase enzymatically converts asparagine into non-functional aspartic acid thereby blocking protein synthesis in a tumor.

Compositions of the MUC1/ECD antagonists of present invention can also be used in combination with antibodies to HER-2, such as Trastuzumab (Herceptin (H)). In addition, the present invention also encompasses the use of MUC1 domain antagonists in combination with epidermal growth factor receptor-interactive agents such as tyrosine kinase inhibitors. Tyrosine kinase inhibitors suitably include imatinib (Norvartis), OSI-774 (OSI Pharmaceuticals), ZD-1839 (AstraZeneca), SU-101 (Sugen) and CP-701 (Cephalon).

When used in the treatment methods of the present invention, it is contemplated that the chemotherapeutic agent of choice can be conveniently used in any formulation which is currently commercially available, and at dosages which fall below or within the approved label usage for single agent use.

V. Ionizing Radiation

In the present invention, the term "ionizing radiation" means radiation comprising particles or photons that have sufficient energy or can produce sufficient energy *via* nuclear interactions to produce ionization (gain or loss of electrons). An exemplary and preferred ionizing radiation is an x-radiation. Means for delivering x-radiation to a target tissue or cell are well known in the art. The amount of ionizing radiation needed in a given cell generally depends on the nature of that cell. Means for determining an effective amount of radiation are well known in the art. Used herein, the term "an effective dose" of ionizing radiation means a dose of ionizing radiation that produces cell damage or death when given in conjunction with the MUC1/ECD antagonists of the present invention, optionally further combined with a chemotherapeutic agent.

Dosage ranges for x-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

Any suitable means for delivering radiation to a tissue may be employed in the present invention, in addition to external means. For example, radiation may be delivered by first providing a radiolabeled antibody that immunoreacts with an antigen of the tumor, followed by delivering an effective amount of the radiolabeled antibody to the tumor. In addition, radioisotopes may be used to deliver ionizing radiation to a tissue or cell.

VI. Downregulation of MUC1/ECD Expression

The present invention also encompass compounds that downregulate MUC1/ECD expression. One such compound is the isocoumarin NM-3 (2-(8-hydroxy-6-methoxy-1-oxo-1 *H*-2-benzopyran-3-yl) propionic acid). NM-3 and other isocoumarins suitable to downregulate the expression of MUC1/ECD are disclosed in U.S. Patent 6,020,363, the entirety of which is herein incorporated by reference. Other suitable compounds include 2-substituted estradiol compounds such as 2-methoxyestradiol and 2-hydroxyrestradiol. These and other suitable estradiol derivatives are disclosed in U.S. Patent 6,239,123, the entirety of which is herein incorporated by reference. Other compounds suitable for downregulating MUC1/ECD expression include

antisense oligonucleotides that target nucleic acid molecules encoding MUC1, as described below.

VII. Antisense Oligonucleotides and Interfering RNA

5 The present invention also employs antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding MUC1 and MUC1/ECD wild-type ligands, such as neuregulin 2 isoforms 5 and 6. Inhibition of MUC1 expression will decrease the levels of MUC1/ECD available for binding to MUC1/ECD ligands. Inhibition of the expression of the endogenous ligands of MUC1/ECD will prevent or decrease the
10 proliferative effect on cancer cells associated with the binding of such ligands to MUC1/ECD. Antisense methodology takes advantage of the fact that nucleic acids tend to pair with "complementary sequences." By complementary, it is meant that polynucleotides are those capable of base-pairing according to the standard Watson-Crick complementary rules. The oligonucleotides of the present invention may be targeted wholly or in part to informational
15 sequences, *i.e.*, those coding for a protein, and other associated ribonucleotides such 5'-untranslated regions, 3'-untranslated regions, 5' cap regions and intron/exon junctions. Thus, the invention provides oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding MUC1 and/or MUC1/ECD wild-type ligands such as neuregulin 2 isoforms 5 and 6. The overall effect of interference with mRNA is modulation of expression of neuregulin
20 isoforms 5 and/or 6. Such modulation can be measured in ways that are routine in the art. In addition, effects on cancer cell proliferation or tumor growth can be assessed.

It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function
25 of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, *i.e.*, under physiological conditions in the case of *in vivo* assays or therapeutic treatment.

The antisense compounds in accordance with this invention preferably comprise from
30 about 4 to about 50 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 linked nucleobases. The oligonucleotides used in

accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis.

The terms "specifically hybridizable" and "complementary" are used to indicate a degree of complementarity sufficient to result in stable and specific binding between the antisense oligonucleotide and the target nucleic acid sequence. An oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide considered "specifically hybridizable" when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility and decrease in expression of the product protein, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences.

The neuregulin 2 protein family comprises a number of alternatively spliced isoforms (Ring *et al.*, 1999). The coding sequences for neuregulin 2 isoforms 5 and 6 share the same nucleotide sequence from exons 1 through 6 of the neuregulin 2 gene that code for the first 416 amino acids of each protein but differ in the sequence coding for the carboxy terminal 10 amino acids of isoform 5 and for the carboxy terminal 6 amino acids of isoform 6. The coding DNA sequences of exons 1 through 6 are incorporated in SEQ ID NO: 10 through SEQ ID NO: 15 respectively. The sequences coding for the first 416 amino acids of isoforms 5 and 6 are nucleotides 313 through 1012 of SEQ ID NO 10, nucleotides 51-222 of SEQ ID NO: 11, nucleotides 230-348 of SEQ ID NO: 12, nucleotides 100 through 220 of SEQ ID NO: 13, nucleotides 111 through 187 of SEQ ID NO: 14 and nucleotides 123 through 181 of SEQ ID NO: 15. The sequences coding for the carboxy terminals of isoform 5 and isoform 6 are nucleotides 132 through 164 of SEQ ID NO: 16 and nucleotides 30 through 50 of SEQ ID NO: 17 respectively.

As SEQ ID NO: 16 and SEQ ID NO: 17 are apparently not shared by other neuregulin gene products, in a preferred embodiment, the antisense oligonucleotide comprises a sequence of at least 4 nucleotides that is complementary to a region between nucleotides 132 and 164 of SEQ ID NO: 16 or nucleotides 30 through 50 of SEQ ID NO: 17. In a more preferred embodiment, the antisense oligonucleotides comprises a sequence of at least 8 nucleotides that is complementary to a region between nucleotides 132 and 164 of SEQ ID NO: 16 or nucleotides 30 through 50 of SEQ ID NO: 17.

In other embodiments, the antisense oligonucleotide comprises a sequence of at least 4 nucleotides that is complementary to a region between nucleotides 313 through 1012 of SEQ ID NO: 10, or a region between nucleotides 51-222 of SEQ ID NO: 11, or a region between nucleotides 230-348 of SEQ ID NO: 12, or a region between nucleotides 100 through 220 of SEQ ID NO: 13, or a region between nucleotides 111 through 187 of SEQ ID NO: 14, or a region between nucleotides 123 through 181 of SEQ ID NO: 15. In another embodiment the antisense oligonucleotide is at least 8 nucleotides that is complementary to a region of the one the foregoing nucleotides sequences.

In other embodiments, the antisense oligonucleotide comprises a sequence of at least 4 nucleotides, and preferably a sequence of at least 8 nucleotides, that is complementary to a non-coding region of SEQ ID NOS: 10 through 17.

In other embodiments of the invention, MUC1 directed antisense oligonucleotides comprise a sequence of at least 4 nucleotides that is complementary to SEQ ID NO: 18. In preferred embodiments, the antisense oligonucleotides comprises a sequence of at least 8 nucleotides that is complementary to SEQ ID NO: 18

The present invention also encompasses expression vectors comprising an expression control system that directs production of a transcript of the foregoing antisense oligonucleotides. In addition, the present invention provides for methods of hybridization comprising providing one of the foregoing antisense oligonucleotides and contacting such oligonucleotide with a nucleic acid comprising the target sequence under conditions that permit hybridization of the oligonucleotide with the nucleic acid. Also included are methods of inhibiting translation of mRNA comprising providing one of the foregoing antisense oligonucleotides and providing a cell comprising mRNA comprising the target sequence and introducing the oligonucleotide into the cell, wherein the oligonucleotide inhibits translation of the mRNA in the cell.

The present invention also encompasses the use of RNA interference ("RNAi") molecules, including small interfering RNA ("siRNA") molecules, as a method of MUC1 gene silencing. siRNA's for mammalian systems are typically composed of double-stranded RNA with 19 to 28, preferable 19 to 23, nucleotide RNA strands, a two nucleotide overhang at the 3' end and an optional 5' phosphate group (Yang *et al.*, 2001; Elbashir *et al.*, 2002). Such siRNA's provide a highly active and selective method for reducing the expression of targeted genes by utilizing the RNA interference post-translational gene silencing pathway. Interference of gene

expression by interfering RNA is recognized as a naturally occurring mechanism for silencing alleles during development in plants, invertebrates and vertebrates. In this pathway, it is believed that siRNA form a protein complex, sometimes termed an "RNA-induced silencing complexes" ("RISC"), that serve to guide a nucleoside to the mRNA whose sequence matches that of the siRNA, resulting in cleavage of that mRNA (Zamore, 2001). Studies on a variety of gene products of different functions and subcellular localizations have demonstrated the general applicability of the siRNA technique of gene silencing (Harborth *et al.*, 2001).

In some embodiments, double-stranded siRNA complexes are designed using the following guidelines:

- (1) a double-stranded RNA complex is composed of a 21-nucleotide sense and 21-nucleotide anti-sense strand, both with a 2-nucleotide 3' overhang, *i.e.*, a 19 nucleotide complementary region;
- (2) a 23 nucleotide sequence is chosen in the coding region of the mRNA with a G:C ratio as close to 50% as possible, preferably within about 60% to about 40%, or alternatively within about 70% to about 30% (to create a 21 base pair duplex with overhangs that match the target sequence and have a 19 base pair complementary region, a target sequence of 23 base pairs is needed);
- (3) preferably avoid regions within about 75 nucleotides of the AUG start codon or within about 75 nucleotides of the termination codon;
- (4) preferably avoid more than three guanosines in a row as poly G sequences can hyperstack and agglomerate;
- (5) preferably choose a sequence that starts with AA as this results in siRNA's with dTdT overhangs that are potentially more resistant to nucleases; and
- (6) preferably the sequence is not homologous to other genes to prevent silencing of unwanted genes with a similar sequence.


A negative control may be included, such a negative control being a nucleotide sequence from a database for a non-existing gene.

Examples of such 21 nucleotide target DNA sequences, and the 19 nucleotide sense and antisense sequences utilizing dTdT 3' overhangs (dT is 2'-deoxythymidine), derived from the sequence of MUC1 mRNA (SEQ ID NO: 19), and preferably the coding sequence of MUC1 mRNA (SEQ ID NO: 20), include, but are not limited to, those described in TABLE 1.

TABLE 1

Target DNA	Sense RNA	antisense RNA
Aaaaggagacttcggctaccc SEQ ID NO: 21	Aaggagacuucggcugcccdtdt SEQ ID NO: 22	gggcagccgaagucuccuudtdt SEQ ID NO: 23
Aaaggagacttcggctaccca SEQ ID NO: 24	Aggagacuucggcuaccadtdt SEQ ID NO: 25	uggguagccgaagucuccudtdt SEQ ID NO: 26
Aaggagacttcggctaccag SEQ ID NO: 27	Ggagacuucggcuaccagdttdt SEQ ID NO: 28	cuggguagccgaagucuccdttdt SEQ ID NO: 29
Aaccagcttcaggtcagctg SEQ ID NO: 30	Ccagcuucagguucagcugdttdt SEQ ID NO: 31	Cagcugaaccugaagcuggdttdt SEQ ID NO: 32
Aacggcacctctgccagggt SEQ ID NO: 33	Cggcaccucugccagggcudtdt SEQ ID NO: 34	Agcccuggcagaggugccgdttdt SEQ ID NO: 35
Aagactgatgccagtagcact SEQ ID NO: 36	Gacugaugccaguagcacudtdt SEQ ID NO: 37	Agugcuacuggcaucagucdttdt SEQ ID NO: 38
Aattguctctggcctccgag SEQ ID NO: 39	uugacucuggccuuccgagdttdt SEQ ID NO: 40	cucggaaggccagagucadtdt SEQ ID NO: 41
Aaggtaccatcaatgtccacg SEQ ID NO: 42	gguaccaucaauguccacgdttdt SEQ ID NO: 43	Cguggacaugaugguaccdttdt SEQ ID NO: 44
Aatgtccacgacgtgaagaca SEQ ID NO: 45	uguccacgacgugaagacadttdt SEQ ID NO: 46	Ugucuucacgucguggacadttdt SEQ ID NO: 47
Aatcagtataaaacggaggca SEQ ID NO: 48	ucaguaaaaaacggaggcadttdt SEQ ID NO: 49	Ugccuccguuuuauacugadttdt SEQ ID NO: 50
Aaaacggaagcagcctctcga SEQ ID NO: 51	aacggaagcagccucucggttdt SEQ ID NO: 52	Ucgacaggcugcuuccguudtdt SEQ ID NO: 53
Aaacggaagcagcctctcgat SEQ ID NO: 54	acggaagcagccucucgaudtdt SEQ ID NO: 55	Aucgagaggcugcuuccgudtdt SEQ ID NO: 56
Aacggaagcagcctctcgata SEQ ID NO: 57	cggaagcagccucucgauadttdt SEQ ID NO: 58	Uaucgagaggcugcuuccgdttdt SEQ ID NO: 59
Aagaactacgggcagctggac SEQ ID NO: 60	gaccuacgggcagcuggacdttdt SEQ ID NO: 61	Auccagcugcccguaguucdttdt SEQ ID NO: 62

The orientation of the double-stranded RNA complex for SEQ ID NO: 22 and SEQ ID NO: 22 is as follows:



The above guidelines are solely an aid to designing suitable RNA oligonucleotides and is not a limitation of the interfering RNA oligonucleotides and related methods of use of the present invention. Thus, also included in the invention are target sequences such as aaggggggttttctgggcctct (SEQ ID NO: 63) and the sense siRNA sequence gggggguuucuggggccucudtdt (SEQ ID NO: 64) and the siRNA antisense sequence agaggcccagaaaaccccdtdt (SEQ ID NO: 65); target sequence aagttcagtgccagctctac (SEQ ID NO: 66) and the sense siRNA sequence guucagugcccagcucuaacddt (SEQ ID NO: 67) and the antisense siRNA sequence guagagcugggcacugaacddt (SEQ ID NO: 68); and target sequence aaggtttctgcaggtaacggt (SEQ ID NO: 69) and the sense siRNA sequence gguuucugcagguaauggudtdt (SEQ ID NO: 70) and the antisense siRNA sequence accauuaccugcagaaacddtdt (SEQ ID NO: 71). Control siRNA sequences include those derived from scrambled target sequences such as ggcgcgtttguaggattcg (SEQ ID NO: 72) and the sense siRNA sequence ggcgcguuuguaggauucgddt (SEQ ID NO: 73) and the antisense siRNA sequence cgaauccuacaagcgcgddtdt (SEQ ID NO: 74).

Also encompassed by the present invention are double-stranded RNA complexes wherein the antisense strand is not exactly complementary to the target mRNA sequence, but can still downregulate MUC-1 expression. Thus, in some embodiments, the antisense strand is a sequence that will hybridize under stringent conditions to the target mRNA sequence. Stringent conditions as used herein means hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1x sodium chloride/sodium citrate (SSC)/0.1% SDS at 68°C (Ausubel *et al.*, eds., 1989, Current Protocols in Molecular Biology, vol. I, John Wiley & Sons, Inc., New York, at p. 2.10.3). In other embodiments, the antisense strand is a sequence that is substantially complementary to the target mRNA sequence. Substantially complementary means that the sequence has up to four mismatched base pairs with the caveat that the double-stranded RNA complex can still effect the downregulation of MUC1. Down-regulation of MUC1 is determined by inhibition in protein

expression by Western blot analysis using specific anti-MUC1 antibodies and/or a RT-PCR analysis specific for MUC1 RNA as compared to a suitable control. In other embodiments, the sense strand has at least a 60% sequence identity to the target mRNA sequence, with the caveat that that the double-stranded RNA complex can still effect the downregulation of MUC1. The
5 extent of sequence identity may be greater than 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% sequence identity. "Sequence identity" as used herein, refers to the subunit sequence similarity of two polymeric molecules, herein oligonucleotides. The identity between two sequences is a direct function of the numbering of matching or identical positions. Identity can be measured using the sequence analysis software
10 BLASTN. The default parameters for comparing two sequences by BLASTN are reward for match = 1, penalty for mismatch = -2, open gap = 5, extension gap = 2.

The double-stranded siRNA complexes of the present invention also encompass hair-pin RNA, in which both strands of a siRNA duplex is included within a single RNA oligonucleotide (Yu *et al.*, 2002; Devroe *et al.*, 2002; Brummelkamp *et al.*, 2002). Thus, for example, the
15 forgoing exemplified complementary sense and antisense RNA sequences may be incorporated into single hairpin RNA oligonucleotides.

In addition to the use of double-stranded siRNA complexes, single strand antisense RNA oligonucleotides can also result in gene silencing utilizing the interference pathway (Martinez *et al.*, 2002). Such single strand antisense RNA is preferably 5' phosphorylated and in mammalian
20 systems is effective from 17 to at least 29 nucleotides in length (Martinez *et al.*, 2002) and in *C. elegans* from between 22 and 40 nucleotides in length (Tijsterman *et al.*, 2002). Thus, one aspect of the present invention is a 5' phosphorylated RNA oligonucleotide of 17 to 40 bases that will hybridize under stringent conditions to SEQ ID NO: 19, wherein SEQ ID NO: 19 represents MUC1 mRNA, or preferably, that will hybridize under stringent conditions to SEQ ID NO: 20,
25 wherein SEQ ID NO: 20 represents the sequence that codes for MUC1. Stringent conditions for hybridization are as defined above. Another aspect of the present invention are 5' phosphorylated RNA oligonucleotides of 17 to 40 bases, wherein the sequences are substantially complementary to a sequence of an equivalent number of bases found in SEQ ID NO: 19, and preferably in SEQ ID NO: 20, and wherein the oligonucleotide will downregulate MUC1 expression in a MUC1
30 expressing cell. Substantially complementary means that the antisense sequence of the double-stranded siRNA complex has up to four mismatched base pairs as compared with the target

mRNA sequence, with the caveat that the 5' phosphorylated RNA oligonucleotide of 17 to 40 bases can still effect the downregulation of MUC1. Another aspect of the invention are 5' phosphorylated RNA oligonucleotide of 17 to 40 bases, wherein the sequences have at least a 60% sequence identity to a sequence of an equivalent number of bases in SEQ ID NO: 75, the antisense sequence complementary to the coding region of MUC1 mRNA, and wherein the oligonucleotide will down-regulate MUC1 expression in a MUC1 expressing cell. Examples of such sequences include, but are not limited to, the 5' phosphorylated derivative of the following 40 nucleotide antisense RNA oligonucleotide sequences, plus 5' phosphorylated sequences of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, and 39 nucleotides in length formed by the removal of contiguous nucleotides from the 3' terminus of the following oligonucleotide sequences:

- 5'-cucauaggggcuacgaucgguacugcuagggggcacauag-3' (SEQ ID NO: 76)
- 5'-cagcugcccguaguucuuucggcggcacugacagacagcc-3' (SEQ ID NO: 77)
- 5'-agacaaugccagcgcaaccagaacacagaccagcaccagc-3' (SEQ ID NO: 78)
- 15 5'-gccuggcaccccagccccagacugggcagagaaaggaaa-3' (SEQ ID NO: 79)
- 5'-gcugacgucugagauagcugcagguuauaucgagaggcugcu-3' (SEQ ID NO: 80)
- 5'-auugaacugugucuccacgucguggacauugaugguaccu-3' (SEQ ID NO: 81)
- 5'-agucaauuguaccaccacagaucugggccugaacuuaaua-3' (SEQ ID NO: 82)
- 5'-aaaacccccuuguuuauaaaucugcaaaaacauuucagaa-3' (SEQ ID NO: 83)
- 20 5'-cucuugguaguagucggugcugggauucucagagaggaa-3' (SEQ ID NO: 84)
- 5'-ugaaaugugaaaagacaggaaaaagaaagagaccccagua-3' (SEQ ID NO: 85)
- 5'-agugcugugauuggaggaggugagaggagguaccgugcua-3' (SEQ ID NO: 86)
- 5'-ggcaucagucuuuggugcuauggcugggcaaggguagga-3' (SEQ ID NO: 87)
- 5'-agaggugccguugugcaccagaguagaagcugagccugau-3' (SEQ ID NO: 88)
- 25 5'-cagggcuggccuggugacugggaccgaggugacaucuguc-3' (SEQ ID NO: 89)
- 5'-cacagcauucucucaguagagcugggcacugaacuucuc-3' (SEQ ID NO: 90)
- 5'-cgcucauaggaugguagguaucccgggucuggaaagauguc-3' (SEQ ID NO: 91)
- 5'-ucuuucggcggcacugacagacagccaaggcaaugagau-3' (SEQ ID NO: 92)
- 5'-caaccagaacacagaccagcaccagcagcgcaugcccca-3' (SEQ ID NO: 93)
- 30 5'-ccccagacugggcagagaaaggaauggcacauacucac-3' (SEQ ID NO: 94)
- 5'-ucgucagguuauaucgagaggcugcuuccguuuuauacug-3' (SEQ ID NO: 95)

5'-ccacgucguggacauugaugguaccuucucggaaggccag-3' (SEQ ID NO: 96)

5'-ccacagauccuggccugaacuuaauauggagaggcccag-3' (SEQ ID NO: 97)

5'-uauaaaucugcaaaaacauuucagaaaugucucucugcag-3' (SEQ ID NO: 98)

5'-cggugcugggaucuuccagagaggaauaaacuggagguu-3' (SEQ ID NO: 99)

5'-aggaggugagaggagguaccgugcuauaggugagugcuacu-3' (SEQ ID NO: 100)

5'-ugcuauaggcuggcaagggugguaggagauacagaguggug-3' (SEQ ID NO: 101)

5'-gcaccagaguagaagcugagccugaugcagagccugaggc-3' (SEQ ID NO: 102)

5'-ugacuggggaccgaggugacauccugucccagguggcagcu-3' (SEQ ID NO: 103)

5'-caguagagcugggcacugaacuucucuggguagccgaagu-3' (SEQ ID NO: 104)

10 Another aspect of the present invention include methods to inhibit MUC1 expression, MUC1-mediated signaling events that leads to inhibition of tumor cell proliferation and induction of tumor cell apoptosis comprising delivering a single-stranded antisense RNA of the present invention into a cell that expresses MUC1.

15 siRNA oligonucleotides can be synthesized, annealed when required, and purified by methods known in the art (*see, e.g., Elbashir et al., 2002, herein incorporated by reference*). Cells may be transfected with siRNA by use of liposomal and other lipid-mediated transfection methodologies (Hohjoh, 2002; Bertrand *et al.*, 2002; Elbashir *et al.*, 2002, all herein incorporated by reference). Alternatively, siRNA's may be expressed in cells transfected with suitable expression cassettes or vectors (Brummelkamp *et al.*, 2002; Sui *et al.*, 2002; Paul *et al.*, 2002) 20 and by the use of viral mediated delivery mechanisms, *e.g.,* adenoviral and retroviral systems, that may be suitably used to express siRNA *in vitro* and *in vivo* (Xia *et al.*, 2002; Devroe & Silver, 2002). In addition to delivery of siRNA molecules, the present invention also encompasses the delivery of longer RNAi molecules by expression constructs. These longer RNAi molecules may effect gene silencing directly or subsequent to enzymatic cleavage by 25 Dicer. The longer RNAi molecule may be a dsRNA molecule wherein the sense is SEQ ID NO: 19 or SEQ ID NO: 20 or a fragment thereof, or in one embodiment is a dsRNA molecule of substantially equivalent size of a dsRNA molecule wherein the sense is SEQ ID NO: 19 or SEQ ID NO: 20, wherein substantially similar means $\pm 10\%$ relative to the number of bp in the aforementioned dsRNA molecules wherein the sense is SEQ ID NO: 19 or SEQ ID NO: 20, wherein the antisense strand will hybridize with SEQ ID NO: 19 or SEQ ID NO: 20 under 30 stringent conditions, as defined previously, or in another embodiment are substantially

complementary, as defined previously, to SEQ ID NO: 19 or SEQ ID NO: 20, or in another embodiment the sense strand has at least 60% sequence identity, as previously defined, to SEQ ID NO: 19 or SEQ ID NO: 20. In various embodiments, The extent of sequence identity may be greater than 60%, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% sequence identity. In other embodiments, the longer the antisense strand of a dsRNAi molecule may comprise one or more of the sequences SEQ ID NOS: 76-104, wherein the dsRNAi molecule is about 100 bp, or about 150 bp, or about 200 bp, or about 250 bp, or about 300 bp, or about 350 bp, or about 400 bp in length.

In the context of the present invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases.

In some embodiments, the oligonucleotides of the present invention may comprise one or more modified internucleoside linkage. Modifications of the normal 3' to 5' phosphodiester linkage include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Examples of the foregoing are taught in WO 99/05160 and U.S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697; 5,625,050; 5,652,355; 5,652,356 and 5,750,674, all of which are herein incorporated by reference.

Other non-phosphorus containing modified linkages include those formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. Examples include morpholino, siloxane, sulfide, sulfoxide, sulfone, sulfonate, sulfonamide, formacetyl, thioformacetyl, riboacetyl, alkene, sulfamate, methyleneimino, methylenehydrazino, amide backbones; and others having mixed N, O, S, and methylene parts. Examples of the foregoing are taught in U.S. Patents 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, all of which are herein incorporated by reference.

In other embodiments, the oligonucleotides of the present invention may comprise one or more modified sugars, including substituted sugars and sugar mimetics. Examples of 2' substituents include OH, halo, amino, cyano, or O, S or N linked alkyl, alkenyl or alkynyl groups, wherein the alkyl, alkenyl and alkynyl groups may be substituted or unsubstituted C₁-C₁₀ alkyl or C₂-C₁₀ alkenyl and alkynyl, or, alkoxyalkoxy, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, or substituted silyl. Examples include 2'-dimethylaminooxyethoxy, 2'-dimethylaminoethoxyethoxy, 2'-methoxy, 2'-aminopropoxy, 2'-CH₂-CH=CH₂, 2'-O-CH₂-CH=CH₂, and 2'-fluoro. The 2'-modification may be in the arabino position or ribo position. Substitutions at the 2' site of sugars also include Locked Nucleic Acids (LNAs) wherein the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. In one embodiment a -CH₂- or -CH₂CH₂- group bridges the 2' oxygen atom and the 4' carbon atom. Similar modifications may also be made at the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Examples of the foregoing are taught in U.S. Patents 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; 5,700,920, and 6,268,490 and U.S. Application No. 20020068708A1, all of which are herein incorporated by reference.

In some embodiments, both the sugar and the internucleoside linkages are modified or replaced with novel groups. One such example is referred to as a peptide nucleic acid (PNA) wherein the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Examples of the foregoing are taught in U.S. Patents 5,539,082; 5,714,331; 5,719,262, and 6,395,474, all of which are herein incorporated by reference.

In further embodiments, the oligonucleotides of the present invention may comprise one or more modified nucleobase. As used in the context of the oligonucleotides of the present invention, "unmodified" nucleobases include the purine bases adenine and guanine, and the pyrimidine bases thymine, cytosine and uracil. Modified nucleobases include other synthetic and natural occurring nucleobases such as 2,6-diaminopurine, 5-methylcytosine, 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-fluoro-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Other examples include tricyclic pyrimidines such as phenoxazine cytidine, phenothiazine cytidine, phenoxazine cytidine, carbazole cytidine, and pyridoindole cytidine. Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Examples of the foregoing are taught in U.S. Patents 3,687,808, 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 5,681,941; 5,750,692, 6,005,096; 6,414,112 and Englisch *et al.*, *Angewandte Chemie*, International Edition (1991), 30, 613, and Sanghvi, Y. S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press (1993), all of which are herein incorporated by reference.

In still further embodiments, the oligonucleotides of the present invention may be linked to one or more moieties or conjugates which enhance the activity, tissue distribution, and/or cellular uptake of the oligonucleotides. Such moieties include but are not limited to, N-9-2-hydroxypropyl)methacrylamide copolymer (Jensen *et al.*, 2002) cholesterol (Letsinger, 1989),
 5 cholic acid (Manoharan *et al.*, 1994), a thioether, (Manoharan *et al.*, 1992; Manoharan *et al.*, 1993), a thiocholesterol (Oberhauser *et al.*, 1992), an aliphatic chain, such as dodecandiol or undecyl residues (Saison-Behmoaras *et al.*, 1991; Kabanov *et al.*, 1990; Svinarchuk *et al.*, 1993), a phospholipid, *e.g.*, di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.*, 1995; Shea *et al.*, 1990), a polyamine or a
 10 polyethylene glycol chain (Manoharan *et al.*, 1995), or adamantane acetic acid (Manoharan *et al.*, 1995), a palmityl moiety (Mishra *et al.*, 1995), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke *et al.*, 1996) or peptides including delivery peptides, *e.g.*, Antennapaedia peptide (Fischer *et al.*, 2002; Zatsepin *et al.*, 2002; Oehlke *et al.*, 2002). Further examples that teach the preparation of such oligonucleotide conjugates include U.S. Patents
 15 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250;
 20 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, all of which are herein incorporated by reference.

Another aspect of the present invention provides for pharmaceutical compositions comprising an oligonucleotide of the present invention and a pharmaceutically acceptable carrier.

25

VIII. Vaccines

The present invention also encompasses the use of MUC1/ECD peptides, *e.g.*, SEQ ID NO: 1 or fragments thereof, wherein such fragments comprise four or more consecutive amino acids of SEQ ID NO: 1, in a vaccine wherein the host mammal generates antibodies to the
 30 polypeptide which also act against the host's own MUC1/ECD. Vaccine preparation techniques

are generally known in the art as described by Duffy (1980), and references cited therein, all of which are incorporated herein by reference.

The MUC1/ECD peptides may be conjugated to a carrier molecule such as a protein or Ficoll. The carrier protein is preferably one with a molecular weight of at least about 40,000 dalton and more preferably at least about 60,000 dalton. The vaccine formulation may comprise a pharmaceutically acceptable carrier and may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. Since the peptides or conjugates may be broken down in the stomach, the vaccine is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

IX. Formulations

The MUC1/ECD antagonists including binding inhibitors or oligonucleotides employed in the compositions and methods of the present invention can be formulated in a variety of conventional pharmaceutical formulations and administered to cancer patients, in need of treatment, by any one of the drug administration routes conventionally employed including oral, intravenous, intraarterial, parental or intraperitoneal.

For oral administration the compositions of the present invention may be formulated, for example, with an inert diluent or with an assimilable edible carrier, or enclosed in hard or soft shell gelatin capsules, or compressed into tablets, or incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of the unit. The amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and the like may also contain the following: a binder, a gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a

disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing a dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, other chemotherapeutic compounds may be incorporated into sustained-release preparation and formulations.

In regard to formulations comprising oligonucleotides, colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure.

Pharmaceutical formulations of the compositions of the present invention which are suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that each syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the compositions of the present invention in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the composition.

X. Treatment Methods

Tumors that can be suitably treated with the methods of the present invention include; but are not limited to, tumors of the brain (glioblastomas, medulloblastoma, astrocytoma, oligodendroglioma, ependymomas), lung, liver, spleen, kidney, lymph node, small intestine, pancreas, blood cells, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow, blood and other tissue. The tumor may be distinguished as metastatic and non-metastatic. Pre-malignant lesions may also be suitably treated with the methods of the present invention.

The treatment with the MUC1/ECD antagonists of the present invention may precede or follow irradiation and/or chemotherapy by intervals ranging from seconds to weeks and/or be administered concurrently with such treatments. In embodiments where the MUC1/ECD antagonists and irradiation and/or chemotherapy are applied separately to the cell, steps should be taken to ensure that a significant period of time does not expire between the time of each delivery, such that the combination of the two or three treatments would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one would

contact the cell with the treatment agents or modalities within amount 0.1 to 25 h of each other and, more preferably, within about 1 to 4 h of each other, with a delay time of only about 1 h to about 2 h being most preferred. In some situations, it is desirable to extend the time period of treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) or several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations. In any case, the invention contemplates that the MUC1/ECD antagonists may be given before, after or even simultaneously with the ionizing radiation and/or chemotherapeutic agent.

Some chemotherapeutic agents transiently induce MUC1 expression on cancer cells 0.5 to 12 hours after contact of the carcinoma cells with the chemotherapeutic agents. Thus, in some embodiments the administration of MUC1/ECD binding inhibitors, especially antibodies to the MUC/ECD sequence SEQ ID NO: 1, optionally conjugated to a toxin or radionucleotide, is coordinated with the increased expression of MUC1 on the cancer cells. In other embodiments, agents other than chemotherapeutic agents may be used to increase MUC1 expression prior to treatment with a MUC1 binding inhibitor, especially antibodies to the MUC/ECD sequence SEQ ID NO. 1, optionally conjugated to a toxin or radionucleotide.

In the methods of the present invention, the actual dosage of MUC1/ECD antagonists employed will depend on a variety of factors including the type and severity of cancer being treated, and the additive or synergistic treatment effects of the MUC1/ECD antagonists and the other treatment modality or modalities selected.

EXAMPLES OF THE INVENTION

Example 1: Peptides

The MUC1/ECD polypeptide sequence, as typically found in MUC1-expressing cells, is provided by SEQ ID NO: 1. A number of polypeptide sequences have been synthesized by standard techniques. These include peptides P1 (SEQ ID NO: 2), P2 (SEQ ID NO: 5) and P3 (SEQ ID NO: 6), which are polypeptide fragments of MUC1/ECD. P1 (SEQ ID NO: 2) represents amino acids 5 through 20 of MUC1/ECD (SEQ ID NO: 1) with a cysteine added at the carboxy terminal. P2 (SEQ ID NO: 5) represents amino acids 13 through 28 of MUC1/ECD (SEQ ID NO: 1) with a cysteine added at the carboxy terminal. P3 (SEQ ID NO: 6) represents amino acids 27 through 44 of MUC1/ECD (SEQ ID NO: 1) with a cysteine at the carboxy terminal. In

addition, the synthesized polypeptide sequence SEQ ID NO: 7 incorporates amino acids 6 through 24 of MUC1/ECD (SEQ ID NO: 1) with a cysteine added at the carboxy terminal. The synthesized polypeptide P0 (SEQ ID NO: 8) incorporates a 19 amino acid sequence occurring in the MUC1 protein occurring just prior to the amino terminus of MUC1/ECD and represents the a potential cleavage site. A cysteine was again added at the carboxy terminal of the sequence at it occurs in the MUC 1 sequence.

Example 2: Anti-MUC1-P1 Antibody

A. Generation of Antibody

The polypeptide P1 (SEQ ID NO: 4), contains the QYK motif and other sequences homologous to ligand binding domains of cytokine receptors (Zrihan-Licht *et al.*, 1994). A polyclonal antibody was raised in rabbits against polypeptide P1 (SEQ ID NO: 4) conjugated to KLH. Serum was prepared by standard methods.

Polyclonal antibodies were also raised against the polypeptide SEQ ID NO: 7, whereby the immunogen was formed by conjugating the polypeptide SEQ ID NO: 7 to KLH. Antibodies have been obtained from 2 rabbits, designated 3402-1 and 3402-2. Both serum and affinity purified antibody preparations have been prepared by standard methodologies.

B. Stimulation of Human Carcinoma Cells by Anti-MUC1-P1-Antibody

Human ZR-75-1 carcinoma cells were grown to 80% confluence in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and then passed onto a 6-well plate at 1×10^4 cells per well. After overnight starvation in medium containing 0.1% FBS, anti-MUC1-P1 antibody was added to each well at the amounts indicated in FIG. 1 and incubated for 48 hours. Cell numbers were quantified after another 3 days of incubation in the presence of 0.1 % FBS. As shown in FIG. 1, anti-MUC1-P1 stimulates the growth of ZR-75-1 cells in a dose dependent fashion.

To assess the specificity of anti-MUC1-P1 antibody stimulation, human MUC1-negative SW480 colon cancer cells were stably transfected to express empty vector (SW480/V) or MUC1 (SW480/MUC1). SW80 colon cancer cells were transfected with either pCMV-IE-ak1-dhfr vector or pCMV-IE-ak1-dhfr-MUC1 using lipofectamide (Ligtenburger *et al.*, 1992). Cells were grown in the presence of 800 $\mu\text{g/ml}$ G418 (neomycin) and serially diluted to single-cell populations. Single cell clones that express MUC1 (SW480/MUC1) were selected. Both

SW480 cells types were grown to 80 % confluence in DMEM containing 10% FBS and plated onto 6-well plates at 5×10^4 cells per well. After overnight starvation in medium containing 0.1% FBS, anti-MUC1-P1 antibody was added at the indicated concentrations and incubated for 48 hr. Cell numbers were quantified after a further day of incubation (3 days total). As shown in FIG. 2, anti-MUC1-P1 stimulates the growth of SW480/MUC1 cells but not SW48-0/V cells. These findings confirm that the anti-MUC1-P1 antibody stimulates the growth of human carcinoma cells by specifically interacting with MUC1.

Example 3: Endogenous MUC1 ECD Ligands

The finding that anti-MUC1-P1 stimulates growth of human carcinoma cells is suggestive of the potential existence of natural MUC1 ECD ligands. To investigate this potential, ZR-75-1 cells were screened as a possible source of MUC1 ligand(s). Conditioned medium was prepared by culturing ZR-75-1 cells in RPMI 1640 medium containing 0.1% FBS for 72 hr and then preparing a supernatant. The conditioned medium was added to SW480/V and SW480/MUC1 cells that were growth arrested in DME containing 0.1% FBS as previously described. Conditioned medium was added at the concentration indicated in FIG. 3 and the cells were maintained for 3 days prior to quantification of cell numbers. As shown in FIG. 3, ZR-75-1 cells express a soluble ligand that stimulates carcinoma cell growth by binding to MUC1.

To identify the soluble MUC1 ligand(s), a fusion protein comprising the MUC1/ECD (SEQ ID NO: 1) and glutathione S-transferase (GST) was prepared. GST was amplified by PCR using a set of primers as follows:

5'-ATTAGGCTAGCCTGGTTCCGCGTGGTTCTATGTCCCCTATACTAGGTTA-3',
and 5'-CAAGGGGATCCCTACGGAACCAGATCCGATTTTGG-3',

and inserted between the NheI and BamHI sites of pET-11d (the "pET-11d-GST vector"). MUC1/ECD was amplified by PCR using a set of primers as follows:

5'-TCTGGCCATGGGAGAAGGTACCATCAAT-3', and
5'-AGCGCGCTAGCCCAGCCTGGCACCCCAGC-3',

and inserted between the Nco1 and Nhe1 sites of pET11d-GST vector (the "pET11d-GST-MUC1/ECD" vector).

The GST fusion protein was prepared by incubating logarithmically growing *E. coli* BL21(D3)pLysS cells transformed with pET11d-GST-MUC1/ECD or pET11d-GST with 0.1 mM isopropyl- β -D-thiogalactopyranoside for 6 hr at 25°C. Cells were pelleted and resuspended in PBS containing 20 % sucrose, 5 mM MgCl₂, 0.5 % NP-40, then sonicated. Debris was removed by centrifugation at 10,000 x g for 30 min. at 4°C. The supernatant was applied to bulk glutathione sepharose 4B and incubated for 4 hr at 4°C prior to washing and packing into a column. The fusion protein was eluted with 10 mM glutathione in 50 mM Tris-HCl, pH 9.5. The purified fusion protein was dialyzed with PBS.

Cytosolic fractions of cultured cells were prepared by harvesting ZR75-1 cells in PBS containing 40mM EDTA. After washing with PBS, cells were resuspended with ice-cold homogenized buffer (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 1 mM dithiothreitol, 1 mM EGTA, 1 mM EDTA and protease inhibitors cocktail (Roche)) and put on ice for 15 min. The suspension was homogenized with a Dounce homogenizer. The homogenate was centrifuged at 1,00 x g for 5 min at 4°C. The supernatant was collected as a cytosol fraction and stored at 0°C.

The GST-MUC1/ECD fusion protein (1.8 mg) was immobilized on 400 μ l of glutathione-sepharose 4B, which was packed into a column and equilibrated with buffer A (30 mM Tris-HCl, pH 7.5, 5 mM MgCl₂, 1 mM EDTA, and 1 mM dithiothreitol). The cytosolic fraction was first precleared by passing it through a glutathione-sepharose 4B column and was then loaded onto the GST-MUC1/ECD affinity column which was then washed twice with 2 x 10 ml of buffer A. The protein bound to the column was eluted by the addition of 2 ml of buffer B (buffer A containing 0.15 M NaCl), and fractions of 0.4 ml each were collected. The second and third fractions were mixed and loaded on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). As a control, the GST protein (1.5 mg) was immobilized on 400 μ l of glutathione-sepharose 4B and the experiment performed as described above. The results demonstrated that MUC1/ECD binds to a 45 kDa protein. A similar experiment was performed with lysates of human MCF-7 breast carcinoma cells confirmed the binding of MUC1/ECD with a 45 kDa protein.

The 45 kDa from the GST-MUC1/ECD adsorbate was excised from the gel, dehydrated with acetonitrile, and then dehydrated with 100 mM ammonium bicarbonate. The gel pieces

were then suspended in 12.5 ng/ μ l trypsin/50 mM ammonium bicarbonate. Digestion was carried out at 37°C for 10-12 hr. The masses of the trypsin-digested peptides were analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectroscopy (MALDI-TOF-MS) using a Voyager DE-PRO (Perceptive Biosystem Inc., Framingham, MA). Two related proteins, designated ML-1 and ML-2, were identified by mass fingerprinting. The sequences of ML-1 (SEQ ID NO: 3) and ML-2 (SEQ ID NO: 4) are as those previously disclosed for two neuregulin isoforms, NRG2 splice isoform 5 and NRG2 splice isoform 6 respectively.

Example 4: MUC1 as an Oncogene

A. MUC1 supports growth in soft agar

The expression of MUC1 was shown to be functionally significant regarding the exhibition of the malignant phenotype. Cell lines that stably express MUC1 were generated. HCT116 colon cancer cells were transfected with pIRES-puro2 vector or pIRES-puro2-MUC1 by lipofectamine and selected for puromycin-resistance. Studies were performed with human MUC1-negative HCT116 colon cancer cells with single clones that stably express either the empty vector (VCT116/V) or MUC1 (HCT116/MUC1). The HCT 116/V and HCT116/MUC1 cells were assayed for anchorage-independent growth in soft agar. Cells (1×10^5 /60 mm dish) were suspended in 0.33% agarose-containing DMEM medium supplemented with 10 % FBS and layered over an agarose plug (0.5 % agarose in DMEM supplemented with 10 % FBS). The cells were incubated to 4 weeks, during which time fresh medium was added to the plates every week. Colonies larger than 70 μ m in diameter were counted after 4 weeks. Expression of wild-type MUC1 was associated with a marked increase in the size and number of colonies compared to that obtained with HCT/116/V cells. These findings were confirmed by similar studies performed with SW480/V and SW480/MUC1 cells wherein MUC1 expression was again shown to support anchorage-independent growth of SW480 cells.

B. MUC1 supports human tumor formation in nude mice

To assess the effects of MUC1 on human tumor growth in vivo. Five to six week old athymic, Balbc/nu/nu mice (Taconic, Germantown, NY) were injected subcutaneously in the right flank with 1×10^6 HCT116/V or HCT 116/MUC1 cells. Tumors (4 mice/group) were measured twice a week. Tumor volumes were calculated by the following formula: $\frac{1}{2}(\text{length} \times$

width²). Experiments were terminated when tumor volume exceeded 2 cm³. Measurements of tumor volume over time demonstrated little HCT116/V cell growth. By comparison there was a marked increase in the growth of HCT116/MUC1 tumors.

5 **Example 5: MUC1 Expression is Induced by Oxidative and Genotoxic Stress**

To determine whether MUC1 is induced in response to oxidative stress, MCF-7 cells were treated with hydrogen peroxide. Cell lysates were analyzed by immunoblotting with anti-DF3/MUC1 antibody. Lysates were prepared by suspending MCF-7 cells in lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 1 mM PMSF, 3 mM NaF, 1 mM sodium vanadate, 1mM DTT with
10 protease inhibitors and either 1% NP-40 or 1% Brij-96) for 30 min on ice. Lysates were cleared by centrifugation and equal amounts of proteins were resolved by SDS-PAGE. Proteins were then transferred to nitrocellulose filters, blocked by incubation in 5 % non-fat dry milk in PBS with 0.05 % Tween-20 and probed with anti-MUC1 antibody (Pandey *et al.*, 1995). Anti-actin was used as a control. The results demonstrated that MUC1 is rapidly and transiently induced in
15 response to oxidative stress while there was no effect of hydrogen peroxide on levels of actin expression.

Similar studies were performed with genotoxic agents. The results demonstrate that treatment of MCF-7 cells with daunorubicin is associated with a rapid and transient induction of MUC1, and not actin, expression. The available evidence indicates that MUC1 is induced by
20 diverse cytotoxic agents, including taxol, cisplatin and ionizing radiation.

Example 6: MUC1 Inhibits the Apoptotic Response to Oxidative and Genotoxic Stress

To determine whether MUC1 inhibits the apoptotic response to oxidative stress, HeLa cells stably expressing the empty vector or MUC1 were treated with 1 mM hydrogen peroxide for
25 1 hr. DNA content was assessed by staining ethanol-fixed cells with propidium iodide and monitoring by FACScan (Beckton Dickerson). Numbers of cells with sub-G1 DNA content were determined with a MODFIT LT program, (Verity Software House, Topsham, ME) (Yuan *et al.*, 1997). The cells were analyzed for induction of sub-G1 DNA by flow cytometry as a marker of apoptosis. As shown in FIG. 4, the results demonstrate that MUC1 inhibits the apoptotic
30 response to oxidative stress.

The induction of apoptosis in cells treated with 0.01 mM taxol for 20 hr was assessed by measuring sub-G1 DNA content of HeLa cells expressing empty vector or MUC1. As shown in FIG. 4, as with oxidative stress, taxol-induced apoptosis was inhibited by MUC1 expression.

5 Example 7: Effect of NM-3 on MUC1 Expression

MCF-7 cells were treated with NM-3 (2-(8-hydroxy-6-methoxy-1-oxo-1 *H*-2-benzopyran-3-yl) propionic acid) at 100-400 µg/ml for 48 hr. DF3 antigen levels were visualized by immunoblot analysis with DF3 MAb (Kufe, U.S. Patent 5,506,343, herein incorporated by reference).

10 A decrease in the intracellular levels of DF3 antigen of NM-3 treated cells relative to non-treated cells was observed. Similar results were found in ZR-75-1 and BT-20 cell lines. The NM-3 mediated decrease of intracellular DF3 antigen was shown to be both dose- and time dependent. To determine whether NM-3 impaired the extracellular localization of the MUC1 DF3 antigen, the antigen levels in cell culture medium supernatants and on MCF-7 cells after
15 NM-3 treatment were investigated. The levels of DF3 antigen were reduced in both localizations. These findings suggest that NM-3 inhibits MUC1 protein expression.

Hybridization studies were performed to determine whether the effect of NM-3 on MUC1-expression was detectable at the transcriptional level. A ³²P-labaelled DF3 DNA probe hybridized to two transcripts of 4.5 and 7.0 kb in total cellular RNA after NM-3 treatment on
20 MCF-7 cells for 48 hr. The levels of both mRNA were decreased relative to controls wherein MCF-7 cells were incubated in the absence of NM-3. The same results were observed using ZR-75-1 and BT-20 cell lines. These findings suggest that DF3 expression is regulated at the transcriptional level after NM-3 treatment on those cell lines.

To determine whether NM-3 inhibits the expression of cellular surface proteins as well,
25 the level of epidermal growth factor receptor (EGF-R) expression after NM-3 treatment was tested on MCF-7, ZR-75-1 and BT-20 cell lines. Compared to controls wherein cells were incubated in the absence of NM-3, there were no detectable changes in EGF-R expression after NM-3 treatment. These results indicate a selective effect of NM-3 on MUC1 expression without inhibition of surface molecular expression.

30

Example 8: Effect of CDDO and Analogs on MUC1 Expression

Cell Culture: Human MCF-7 breast carcinoma and HeLa cervical carcinoma cells (obtained from the ATCC, Manassas, VA) were grown in DMEM (high glucose; Mediatech, Cellgrow) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 2mM L-glutamate. Cells were treated with oleanane triterpenoid 2-cyano-3,12-dioxoolean-1,9-diene-28-oic (CDDO) CDDO methyl ester (CDDO-Me), imidazole CDDO (CDDO-Im) or the 2-propyl-imidazole CDDO (CDDO-Pr-Im). In ceratin experiments, cells were treated with N-acetylcysteine (NAC; Sigma Chemical Co.) or glutathione (GSH; Sigma Chemical Co.).

Immunoblot analysis: Cells were lysed in ice-cold lysis buffer (20mM Tris-HCl, pH 8.0, 150mM NaCl, 1% Triton-X-100, 1 mM phenylsulfonyl fluoride, 1 mM DTT, 10 µg/ml aprotinin) for 30 min. Lysates were cleared by centrifugation for 20 min at 4°C as described (Yin *et al.*, 2001). Proteins were separated by SDS-PAGE, transferred to nitrocellulose and probed with anti-DF3/MUC1 (U.S. Patent 5,506,34) or anti-β-actin (Sigma). The antigen-antibody complexes were visualized by enhanced chemiluminescence (ECL; Amersham Life Sciences).

Reverse transcription-polymerase chain reaction (RT-PCR): Total cellular RNA was extracted in Triazol, dissolved in RNAase-free water and incubated for 10 min. at 55°C. MUC1-specific primers (5'-TCTACTCTGGTGCACAACGG-3' and 3'-TTATATCGAGAGGCTGCTTCC-5') were designed to span a region within the genomic DNA that contains two introns and result in amplification of a 489-bp fragment from RNA and a 783-bp fragment from genomic DNA. RNA-specific primers for human β-actin were used as a control. The RNA was reverse transcribed and amplified using SuperScript One-Step RT-PCR with Platinum Taq (GIBCO-BRL Gaithersburg, MD). Amplified fragments were analyzed by electrophoresis in 2% agarose gels.

Measurement of ROS levels: Cells were incubated with 10 mM DCF-DA (Sigma) for 15 min at 37°C to assess ROS-mediated oxidation of the fluorescent compound DCF (LeBel *et al.*, 1992). Fluorescence of oxidized DCF was measured at an excitation wavelength of 480 nm and an emission wavelength of 525 nm using a flow cytometer (Beckton Dickinson, Lincoln Park, NJ).

CDDO downregulates MUC1 expression: MUC1-positive cells were treated with CDDO at concentrations of 1, 3 and 5 µM. Immunoblot analysis of cell lysates with anti-MUC1

demonstrated little if any effect of 1 or 3 μ M CDDO at 24 hr while exposure to 5 μ M CDDO was associated with decreased levels of MUC1 protein. By contrast, 5 μ M CDDO had no apparent effect on β -actin gene expression. Studies with 1 μ M CDDO-Me also demonstrated downregulation of MUC1 expression that was detectable at 12 hr and nearly complete at 24 hr. Other substituents of the carboxyl group at C-17 of CDDO were effective in downregulating MUC1 expression. For example, both the imadazole derivative CDDO-Im and 2-propyl-imadazole derivative CDDO-Pr-Im decreased levels of MUC1 protein at a concentrations of 0.8 μ M.

To determine whether MUC1 expression is decreased at the mRNA level, RT-PCR was performed on MCF-7 cells treated with CDDO and the derivatives. The results demonstrate that CDDO treatment is associated with a decrease in MUC1, but not β -actin, transcripts. Similar findings were obtained with CDDO-Me, CDDO-Im and CDDO-Pr-Im. Whereas CDDO induces apoptosis of diverse cell types, we assessed viability of MCF-7 cells under the same experimental conditions. The results demonstrate that CDDO and its derivatives have little if any effect on MCF-7 cell viability at 24 hours of exposure. By contrast, longer periods of treatment (48 and 72 hr) were associated with detectable decrease in viability.

Studies were also performed with MUC1-positive HeLa cervical carcinoma cells. The results demonstrate that CDDO, CDDO-Me, CDDO-Im and CDDO-Pr-Im decrease MUC1 expression at concentrations below decrease expression at concentrations below 1 μ M. RT-PCR studies with HeLa cells also demonstrated that these agents decrease MUC1 transcripts.

CDDO increase intracellular ROS levels: Cells were incubated with DCF-DA and ROS-mediated oxidation of the fluorochrome was assessed by flow cytometry. Compared to control MCF-7 cells, treatment with CDDO was associated with detectable increases in ROS. As a control, cells were incubated with NAC, a scavenger of ROS. NAC pretreatment was associated with abrogation of CDDO-induced ROS production. Similar findings were obtained with CDDO-Me, CDDO-Im and CDDO-Pr-Im. The effects of CDDO and the derivatives on ROS were comparable to that found following exposure to 0.1 mM H_2O_2 .

CDDO-induced downregulation of MUC1 is blocked by antioxidants: To determine whether the increases in ROS contribute to the downregulation of MUC1 expression, cells were pretreated with NAC and then incubated with CDDO or one of the derivatives. The results demonstrate that CDDO-, CDDO-Me-, CDDO-Im- and CDDO-Pr-Im-induced decreases in

MUC1 are blocked by NAC. Treatment of cells with the antioxidant GSH also blocked the effects of CDDO and the derivatives on MUC1 expression. In concert with these results, treatment of cells with 0.1 mM H₂O₂ was associated with downregulation of MUC1 and this response was reversed with NAC. These finding support a model in which CDDO and its derivatives decrease MUC1 expression by a ROS-mediated mechanism.

Example 9: Effect of siRNA on MUC1 Expression

Cell Culture: Human MCF-7 breast cancer cells were maintained in DMEM supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin mixture. Human A549 non-small cell lung cancer cells were maintained in RPMI1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin mixture.

siRNAs: Five different double-stranded anti-MUC1 siRNAs were designed: one against the target sequence SEQ ID NO: 63, *i.e.*, AAGGGGGT TTTCTGGGCCTCT, with sense and antisense strands as shown in SEQ ID NO: 64 and SEQ ID NO: 65 respectively (hereinafter siRNA #1); one against the target sequence SEQ ID NO: 42, *i.e.*, AAGGTACCATCAATGTCCACG, with sense and antisense strands as shown in SEQ ID NO: 43 and SEQ ID NO: 44 respectively (hereinafter siRNA #2); one against the target sequence SEQ ID NO: 21, *i.e.*, AAAAGGAGACTTCGGCTACCC, with sense and antisense strands as shown in SEQ ID NO: 22 and SEQ ID NO: 23 respectively (hereinafter siRNA #3); one against the target sequence SEQ ID NO: 66, *i.e.*, AAGTTCAGTGCCCAGCTCTAC, with sense and antisense strands as shown by SEQ ID NO: 67 and SEQ ID NO: 68 respectively (hereinafter siRNA #4); and one against target sequence SEQ ID NO: 69, *i.e.*, AAGGTTTCTGCAGGTAACGGT, with sense and antisense strands as shown by SEQ ID NO: 70 and SEQ ID NO: 71 respectively (hereinafter siRNA #5). A control siRNA was designed against the scrambled target SEQ ID NO: 72 with sense and antisense strands as shown by SEQ ID NO: 73 and SEQ ID NO: 74 respectively. Each RNA sense oligonucleotide (50 μM) was combined with equal volume of antisense oligonucleotide (50 μM) in an annealing buffer (20 mM KCl, 6 mM HEPES-KOH, pH 7.5, 0.2 mM MgCl₂). The solution was incubated for 1 min at 90°C to denature secondary structure, and placed at 37°C for 1 hour to anneal the complementary strands. The subsequent double-stranded RNAs were used as the anti-MUC1 siRNA.

Transfection: Cells ($1-3 \times 10^5$ cells/well) were plated in 6-well plates in growth medium without antibiotics, and incubated overnight. After washing cells once with Opti-MEM I (Invitrogen), 800 μ L of fresh Opti-MEM I and 200 μ L of the mixture of anti-MUC1 siRNA (final concentration: 0.2–0.6 μ M) and Oligofectamine Reagent (Invitrogen) were added to the cultured cells. Four hours later, 300 μ L of FBS was added to the cultured cells.

Western Blot Analysis: Cell were passed a day before transfection. MUC1 siRNA (0.2 micromolar) was added with oligofectamine to cells in 0% FBS. Four hours later serum was added to a final concentration of 10%. After various time intervals (48h, 72h and 96h), cells were washed and total cell lysates were prepared. Proteins were separated from cell lysates by SDS-PAGE, transferred to nitrocellulose and analyzed by immunoblotting with anti-DF3 antibodies.

RT-PCR: Total RNA was extracted and purified from cultured cells using RNazol B according the manufacturer's instructions. The RNA was quantified by determining absorbance at 260 nm. One μ g of total RNA from each sample was reverse transcribed into cDNA using Thermoscript reverse transcriptase (Invitrogen) in a volume of 20 μ L. The cDNA product was amplified by PCR using Platinum Taq DNA polymerase (Invitrogen) and specific primers for MUC1 and beta-actin as an internal control. The sequences of primers used were as follows; MUC1 (forward, 5'-GGTACCATCAATGTCCACG-3'; reverse, 5'-

CTACAAGTTGGCAGAAGTGG-3') and β -actin (forward, 5'-ATCATGTTTGAGACCTTCAA-3'; reverse, 5'-CATCTCTTGCTCGAAGTCCA-3').

The reaction was performed using the following program: 94°C for 2 min, 29 cycles (25 cycles for beta-actin) at 94°C for 2 min, 48°C for 1 min, 72°C for 30s and then additional extension step of 72°C for 10 min. The PCR products were separated on a 2% agarose gel, stained with ethidium bromide and photographed under UV light.

SiRNA downregulates MUC1 expression: As shown in FIGS. 5A-D, both double-stranded siRNA's #1 and #2 downregulate MUC1 expression at both the protein level, as shown by the immunoblot results, and at the RNA level, as shown by the RT-PCR results, in both MCF-7 and A549 cells. FIG. 6 shows the downregulation of MUC1 expression by siRNAs #3, #4 and #5 in MCF-7 cells at the protein level by immunoblot.

Example 10: Combination of MUC1 Directed siRNA and Cisplatin (CDDP) on Human Non-small Cell Lung Cancer A549 cells

Cell culture: Human non-small cell lung cancer A549 cells were grown in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml of penicillin and 100 µg/ml of streptomycin, respectively.

Transfection with siRNA: Cells (3×10^5 cells/well) were plated in 6-well plates in growth medium without antibiotics, and incubated overnight. Cells were then transfected with MUC1 siRNAs, siRNA #1, *i.e.*, one against the target sequence SEQ ID NO: 63, *i.e.*, AAGGGGGTTTTCTGGGCCTCT with sense and antisense strands as shown in SEQ ID NO: 64 and SEQ ID NO: 65 respectively; and siRNA #2, *i.e.*, one against the target sequence SEQ ID NO: 42, *i.e.*, AAGGTACCATCAATGTCCACG with sense and antisense strands as shown in SEQ ID NO: 43 and SEQ ID NO: 44 respectively, and one control siRNA directed towards the non-specific gene target AAGCGCGCTTTGTAGGATTCG using Oligofectamine reagent (Invitrogen) according to the manufacturer's instructions. After 24 hr of transfection, the medium was changed to complete medium containing antibiotics.

Treatment of Cells with cisplatinum (CDDP): At 72 hr post transfection of siRNAs, 10 µM CDDP was added to the cells in fresh culture medium. After 48 hr of CDDP exposure cells were trypsinized and analyzed for MUC1 expression and apoptosis as described below.

Apoptosis assay.: A549 cells were initially stained for MUC1 expression using the DF3 monoclonal antibody (U.S. Patent 5,506,343, herein incorporated by reference). Cells (approx. 6×10^5 per well) were trypsinized for approx. 5 minutes with 0.5 ml per well (of 6 well plate), of a 0.05% trypsin solution, after which 1.0 ml of 10% FBS containing DMEM medium was added to inhibit trypsin activity. Two wells per treatment group were combined to generate the sample for staining. Cells were pelleted by centrifugation at approx. 300xg, then resuspended in 2ml staining buffer (PBS with 1% BSA, and 0.1% sodium azide). Cells were transferred to a 3ml polystyrene tube and pelleted again. The cell pellet was resuspended in 200 µl of staining buffer containing DF3 monoclonal antibody at a concentration of 500 ng/ml. Binding of the DF3 antibody was carried out at 4°C for 1 hour with gentle rocking of the tubes in an upright rack. The amount of DF3 staining was then measured using a biotinylated goat anti-mouse secondary antibody (diluted 1:200 in staining buffer) and streptavidin-conjugated phycoerythrin (diluted 1:50 in staining buffer). After fluorescent staining for MUC1 expression, apoptosis was

determined by staining cells with Annexin V-FITC and propidium iodide (PI). Stained cells were washed once with binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl₂], and then resuspended in 200 µl of binding buffer containing 0.5 µg/ml annexin V-FITC (Clontech Laboratories) and 1.25 µg/ml PI (Clontech). Staining of apoptotic cells was allowed to proceed at room temperature for 20 minutes with gentle shaking. Cells were again pelleted, washed with 1ml of binding buffer and resuspended in 0.5 ml binding buffer for analysis of apoptosis. Using a flow cytometer, (EPICS XL-MCL, Coulter Corp), the amount of MUC1 expressing cells were determined using the FL2 detector, annexin V-FITC staining was measured in the FL1 detector and propidium iodide staining was measured in the FL3 detector. Overlapping signal or bleed over between the detectors was compensated for using control cells stained with only one of each of the fluorescent dyes.

MUC1 siRNAs Enhance the Efficacy of CDDP: FIG. 7 shows that MUC1 siRNA # 2 transfected A549 cells exhibited an increase in the percentage of apoptotic cells relative to controls and also more than additively enhances the percentage of apoptotic cells when combined with CDDP exposure. FIG. 8 also shows that transfection of both siRNA #1 and siRNA #2 decreased the proliferation of A549 cells.

Example 11: Construction of plasmids that expresses MUC1 siRNA

Plasmids expressing hairpin MUC1 siRNA (targeted sequence, 5'-AAGGTACCATCAATGTCCACG-3') were constructed by using expression vectors with different promoters, pSilencer (U6 promoter, Ambion) and pSuper (H1 promoter, OligoEngine). To insert the target sequence that encodes the MUC1 siRNA, the following DNA oligos were synthesized, annealed and cloned into the *Apa* I and *EcoR* I site of pSilencer (pSilencer/MUC1siRNA) and the *Bgl* II and *Hind* III site of pSuper (pSuper/MUC1siRNA), respectively.

pSilencer,

5'-GGTACCATCAATGTCCACGTTCAAGAGACGTGGACATTGATGGTACCTTTTTT-3'

and

5'-

AATTAAAAAAGGTACCATCAATGTCCACGTCTCTTGAACGTGGACATTGATGGTACCGGCC-3'

pSuper,

5'-

GATCCCCGGTACCATCAATGTCCACGTTCAAGAGACGTGGACATTGATGGTACCTTT
TTGGAAA-3' and 5'-

5 AGCTTTTCCAAAAAGGTACCATCAATGTCCACGTCTCTTGAACGTGGACATTGATGG
TACCGGG-3'

The structure of an expression plasmid containing the anti-MUC1 siRNA #2 is shown in FIG. 9.

Transfection with MUC1 siRNA expression plasmids. Human breast cancer MCF-7
10 and ZR-75-1 cells were transfected with pSilencer/MUC1siRNA and pSuper/MUC1siRNA by
using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Human
multiple myeloma RPMI8226 and U266 cells were also transfected by electroporation of 4×10^6
cells with 20 μ g pSilencer/MUC1siRNA or 30 μ g pSuper/MUC1siRNA in 0.4 ml of RMPI1640
medium. Electroporation was performed by the Gene Pulser (Bio-Rad Laboratories) at 0.22 kV
15 and 960 μ F capacitance. To obtain the stable transfectants, cells were cotransfected with a
plasmid carrying a neomycin-resistance gene (pCIneo, Promega), followed by selection in
medium containing 400–600 μ g/ml G418.

MCF-7 cells transfected with pSilencer/MUC1siRNA or vector were harvested at 48 hr
post transfection and subjected to Western blot analysis with anti-MUC1 antibody (DF3). The
20 results showed down-regulation of MUC1 protein expression.

Example 12: Generation of Monoclonal Antibody IPB-01

A chimeric protein containing the mouse Fc region and the extracellular domain of
MUC1-Y was prepared for use as an antigen. Full-length cDNA of MUC1-Y (Baruch *et al.*,
1997) was constructed in three steps of PCR. In the first PCR, cDNA coding for MUC1 signal
25 peptide was made with the MUC1 primers:

(5'-CTAGCTAGVATGACACCGGGCACCC-AGTC-3', and
5'-GGAATTAAAAGCATTCTTCTCAGTAG-3'.

Then the primers:

5'-AATGCTTTTAATTCCTCTCTG-3', and
30 5'-CTTAAGCTACAAGTTGGCAGAAAGT-3',

were used for the second PCR to produce cDNA of MUC1-Y without signal peptide. The mixture of first and second PCR products was taken as a template, and the full-length of MUC1-Y cDNA was amplified in the third PCR with the primers:

5'CTAGCTAGC-ATGACACCGGGCACCCAGTC-3', and

5'-CTTAAGCTACAAGTTGGCAGAAGT-3'.

After digestion of both MUC1-Y cDNA and pIRESpuro2 vector (Clontech Lab., Inc) with *Nhe I* and *Aft II*, DNA fragments were separated on 1.2% agarose gel. MUC1-Y DNA was purified and ligated into pIRESpuro2 vector. The construct was confirmed by both enzymes digestion and DNA sequencing.

The cDNA sequences of mouse IgG1 Fc fragment and human IgG2a Fc fragment was cloned in to expression vector, pEF6/V5.His (Invitrogen Cat# V96120), resulting in pEF6/V5.His-mFc and pEF6/V5.His-hFc. The cDNA of the extracellular domain of MUC1-Y (MUC1-Yex) was amplified by PCR using the primers:

MUC1/Yex-N-NheI: 5'-CCC ACC GCT AGC ACC ACC ACC ATG ACA CCG-3',

MUC1/Yex-C-HindIII: 5'-CCA GCC AAG CTT CCC AGC CCC AGA CTG GGC-3',

and cloned, in frame, upstream of mFc sequence in pEF6/V5.His-mFc resulting in pEF6/V5.His-MUC1/Yex-mFc. The expression plasmid was confirmed by DNA sequencing.

The expression plasmid was transfected into 293 or CHO K1 cells by lipofectamine. For transient transfection, 293 cells were cultured 72 hr after transfection, and the supernatant was collected. Chimeric protein was purified by chromatography using protein A column. For stable transfection, transfected CHO K1 cells were selected by antibiotics, and single clones were selected and expanded. Cell culture supernatant was passed through a protein A column to purify this chimeric protein.

The chimeric protein as expressed contained the MUC1-Y extracellular domain plus the N-terminal sequence (SEQ ID NO: 105):

MTPGTQSPFFLLLLLTAVLTATTAPKPVVTGSGHASSTPGGEKETSATQRSSVPSSTEKN
AFNSSLEDPSTDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTIN
VHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAG.

Upon secretion from the cell, the N-terminal sequence was cleaved resulting in a mFc chimeric protein containing the 102 amino acid MUC1-Y extracellular sequence (SEQ ID NO: 106):

FNSSLEDPSTDYYQELQRDISSEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINV
HDVETQFNQYKTEAASRYNLTISDVSVDVFPFSAQSGAG.

Purified MUC1-Y-mFc protein used to immunize BALB/C mice according to the following schedule:

- 5 Day 0: 50 µg antigen/animal in Freund's Complete Adjuvant
- Day 14: 40 µg/animal in Freund's Incomplete Adjuvant
- Day 35: 40 µg/animal in Freund's Incomplete Adjuvant
- Day 45: Test bleed
- Day 56: Final boost 15 µg IV and 15 µg/IP in PBS
- 10 Day 59: Fusion

The splenocytes of the mice with high titer against antigen were isolated and fused to BALB/C derived myeloma cell lines, X63-Ag8.653 or P3, in the presence of PEG. Hybridomas were selected in HAT media. Selected hybridomas were tested against the antigen by solid phase ELISA and positive hybridomas were cloned by serial dilution and limited dilution. After at least
15 two rounds of cloning and testing, positive clones were expanded and tested in solid phase ELISA, flow cytometry, epitope mapping and growth assays.

For the solid phase ELISA assay, Dynex Immulon 1B plates were coated overnight at 4°C with 100 µl MUC1-Yex-mFc solution containing 1 µg/ml of protein in Coating Buffer (0.1M carbonate/bicarbonate buffer, pH 9.6), and blocked with 200 µl/well of PBS (Ca²⁺/Mg²⁺ Free) containing 4% Non Fat Dry Milk and 0.05% Tween-20. Hybridoma supernatants were then
20 added followed by incubation at room temperature for 2 hr. The plates were washed 4 times with PBS containing 0.05% Tween-20 and incubated at room temperature for 1 hr with 100 µl rabbit HRP-labeled anti-mouse antibody at a 1:10,000 dilution. After washing, 100 µl of TMB substrate was added to each well and incubated for 10 minutes at room temperature. The reaction was
25 stopped by addition of 100µl stop solution. The plates were read at 450 nm.

An antibody designated IPB-01 was peptide mapped to a sequence designated as A-1 (SEQ ID NO: 107) FNSSLEDPSTDYYQELQRD. The binding of IPB-01 to immobilized MUC1-Yex-mFc is shown in FIG. 10. The binding to MUC1 expressed on the cell surface was determined by flow cytometry. HTC cells were transfected with the expression plasmids for
30 MUC1/Y or the empty expression vector by Lipofectamine (Invitrogen Cat#18324). Transfectants were selected for antibiotics resistance for 2 weeks. Single clones were then

selected and expended. Expression of MUC1-Y was confirmed by Western analyses and flow cytometry for specific binding of antibodies against the tandem repeats of MUC1-Y (DF3E). In addition, MCF-7 human breast cancer cells that express full length MUC1 endogenously were also used for the flow analyses. For the determination of the binding of IPB-01, cells were

5 incubated with IPB-01 or isotype control antibody for 2 hr at 4°C. Cells were washed and incubated in FACS buffer (PBS containing 0.1% Bsa and 0.1% NaN₃), containing biotin-conjugated anti-mouse antibody for 1 hr at 40°C. After incubation, cells were washed and incubated with PE-conjugated streptavidin and analyzed using a Beckman Coulter flow cytometer. IPB-01 was determined to bind to MUC1-Y but not full length MUC1 as expressed

10 on the cell surface. This specificity of binding was verified by immunofluorescent microscopy. Cells expressing full length MUC1 or MUC1-Y were grown in multi-chamber slides and incubated with IPB-01 for 1 hr at room temperature. Cells were washed and incubated with FITC-conjugated anti-mouse IgG and the binding of IPB-01 to cells was analyzed by fluorescence microscopy. IPB-01 was observed to bind only to MUC1-Y expressing cells.

15 Monoclonal antibody IPB-01 may suitably be used for diagnostic uses, e.g., directly or indirectly labeled by a suitable fluorophore or chromophore, or as a therapeutic agent, e.g., as when attached to a toxin or radiolabel.

Example 13: Generation of Monoclonal Antibody IPB-02

The DNA sequence representing the 100 amino acid MUC1-ECD region (SEQ ID NO: 20 108):

SSLEDPSTDYYQELQRDISSEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHD
VETQFNQYKTEAASRYNLTISDVSVDVPFPFSAQSGAG

was amplified by RT-PCR and cloned into His-tagged expression plasmid, pET-28a (Novagen, Cat# 69864-3). The plasmid was introduced to *E. coli* bacterial strain, BL21(DE3) (Novagen
25 Cat#69387) by heat shock transformation. Large scale of bacterial cells was cultured and production of His-ECD was induced by IPTG at 1 mM for 5-6 hr. Bacterial cells were collected by centrifugation and lysed with Benzonase Nuclease (Novagen Cat#70664-3) and lysozyme. The inclusion bodies were purified and His-ECD protein was purified, under denatured condition, using Ni-column chromatography. Purified protein was then refolded by serial
30 dialyses to exclude the denaturing agent, urea.

His-ECD was conjugated to KLH and used to immunize BALB/C mice according to the following schedule:

- Day 0: 50 µg antigen/animal in Freund's Complete Adjuvant
- Day 14: 40 µg/animal in Freund's Incomplete Adjuvant
- 5 Day 35: 40 µg/animal in Freund's Incomplete Adjuvant
- Day 45: Test bleed
- Day 56: Final boost 15 µg IV and 15 µg/IP in PBS
- Day 59: Fusion

The splenocytes of the mice with high titer against antigen were isolated and fused to
 10 BALB/C derived myeloma cell lines, X63-Ag8.653 or P3, in the presence of PEG. Hybridomas were selected in HAT media. Selected hybridomas were tested against the antigen by solid phase ELISA and positive hybridomas were cloned by serial dilution and limited dilution. After at least two rounds of cloning and testing, positive clones were expanded and tested in solid phase ELISA, flow cytometry, epitope mapping and growth assays.

15 For the solid phase ELISA assay, Dynex Immulon 1B plates were coated overnight at 4°C with 100 µl His-ECD solution containing 1 µg/ml of protein in Coating Buffer (0.1M carbonate/bicarbonate buffer, pH 9.6), and blocked with 200 µl/well of PBS (Ca⁺⁺/Mg⁺⁺ Free) containing 4% Non Fat Dry Milk and 0.05% Tween-20. Hybridoma supernatants were then added followed by incubation at room temperature for 2 hr. The plates were washed 4 times with
 20 PBS containing 0.05% Tween-20 and incubated at room temperature for 1 hr with 100 µl rabbit HRP-labeled anti-mouse antibody at a 1:10,000 dilution. After washing, 100 µl of TMB substrate was added to each well and incubated for 10 minutes at room temperature. The reaction was stopped by addition of 100 µl stop solution. The plates were read at 450 nm.

An antibody designated IPB-02 was peptide mapped to a sequence designated as P-0
 25 (SEQ ID NO: 109) SNIKFRPGSVVVQLTLAFRE. The binding of IPB-02 to immobilized His-ECD is shown in FIG. 10. The binding to MUC1 expressed on the cell surface was determined by flow cytometry. HTC cells were transfected with the expression plasmids for MUC1/Y or the empty expression vector by Lipofectamine (Invitrogen Cat#18324). Transfectants were selected for antibiotics resistance for 2 weeks. Single clones were then selected and expended.
 30 Expression of MUC1-Y was confirmed by Western analyses and flow cytometry for specific binding of antibodies against the tandem repeats of MUC1-Y (DF3E). In addition, MCF-7

human breast cancer cells that express full length MUC1 endogenously were also used for the flow analyses. For the determination of the binding of IPB-02, cells were incubated with IPB-02 or isotype control antibody for 2 hr at 40°C. Cells were washed and incubated in FACS buffer (PBS containing 0.1% BSA and 0.1% NaN₃), containing biotin-conjugated anti-mouse antibody
5 for 1 hr at 40°C. After incubation, cells were washed and incubated with PE-conjugated streptavidin and analyzed using a Beckman Coulter flow cytometer. IPB-02 was determined to bind to both full length MUC1 and MUC1-Y expressed on the cell surface.

Monoclonal antibody IPB-02 may suitably be used for diagnostic uses, *e.g.*, directly or indirectly labeled by a suitable fluorophore or chromophore, or as a therapeutic agent, *e.g.*, as
10 when attached to a toxin or radiolabel.

Example 14: *In Vitro* and *In Vivo* Down-regulation of MUC1 and Sensitization to Chemotherapeutic Agents by Transduction of Cancer Cells with a Retroviral Vector

Cell culture: Human HCT116 cells (ATCC, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium/F12 with 10% heat-inactivated fetal calf serum (FCS), 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamate. Human ZR-75-1 breast carcinoma cells (ATCC, Manassas, VA) were grown in RPMI 1640 medium containing 10%
20 FCS, antibiotics and 2mM L-glutamate. HCT cells were transfected with pIRES-puro2 or pIRESpuro2-MUC1 as described (Li *et al.*, 2001a).

Subcellular fractionation: Purified mitochondria were prepared as described (Kumar *et al.*, 2003). Cell membranes were purified from supernatants after sedimentation of mitochondria as described (Kharbanda *et al.*, 1996).

Analysis of mitochondrial transmembrane potential: Cells were incubated with 0.5 nM 3,3-dihexyloxocarbocyanine iodide (DiOC₆[3]; Molecular Probes) for 30 min and analyzed by flow cytometry as described (Shapiro, 2000).

Immunoblot analysis: Lysates were prepared from cells as described (Li *et al.*, 2001]. Equal amounts of protein were separated by SDS-PAGE and transferred with anti-cytochrome c
30 (BD PharMingen, San Diego, CA). The immunocomplexes were detected with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (ECL, Amersham Biosciences, Piscataway, NJ). Intensity of the signals was determined by densitometric scanning.

Apoptosis assay: Apoptotic cells were quantified by analysis of sub-G1 DNA. Cells were harvested, washed with PBS, fixed with 80% ethanol, and incubated in PBS containing 20 ng/ml RNase (Roche) for 60 min at 37°C. Cells were stained with 40 µg/ml propidium iodide (Sigma) for 30 min at room temperature in the dark. DNA content was analyzed by flow cytometry (EPICS XL-MCL, Coulter Corp.).

Generation of retroviral vectors expressing MUC1siRNA: Oligonucleotides of siRNA were designed that contained a sense strand or 19 nucleotide sequences of MUC1 (based on MUC1 DNA target SEQ ID NO: 42) followed by a short spacer (GAGTACTG), the reverse complement of the sense strand, and five thymidines as an RNA polymerase III transcriptional stop signal. Forward oligonucleotides for MUC1 were TCGAGGGTACCATCAATGTCCACGGAGTACTGCGTGGACATTGATGGTACCTTTTT (SEQ ID NO: 110) including a *Xho I* cleavage site and the reverse CTAGAAAAAGGTACCATCAATGTCCACGCAGTACTCCGTGGACATTGATGGTACCC (SEQ ID NO: 111) including a *Xba I* site. Oligos were annealed and cloned into the *Xho I-Xba I* site of the pSuppressorRetro vector (Imgenex Co., San Diego, CA). 293T cells were cotransfected with a plasmid expressing MUC1siRNA and pCL Amphi virus using Fugene (Roche, Indianapolis). The supernatant was collected after 48 h for infection of target cells.

Results: Infection of ZR-75-1 breast carcinoma cells with the MUC1siRNA reterovirus and selection in G418 resulted in stable downregulation of MUC1 expression. As a control, stable transfection of ZR-75-1 cells with the empty reterovirus had no effect on MUC1 expression. Cisplatin (CDDP) treated ZR-75-1/vector cells exhibited little if any decrease in mitochondrial transmembrane potential ($\Delta\Psi_m$). By contrast, CDDP treatment of ZR-75-1/MUC1siRNA cells was associated with a clear loss of $\Delta\Psi_m$. In concert with these findings, cytochrome C release, as measured by immunoblot, was attenuated in CDDP-treated ZR-75-1/vector cells, as compared to ZR-75-1/MUC1siRNA cells. In the absence of exposure to a cytotoxic agent, ZR-75-1 cells expressing the empty viral vector or MUC1siRNA exhibited less than 5% apoptosis. Treatment of ZR-75-1/vector cells with CDDP was associated with the induction of approximately 25% apoptosis. Notably, treatment of ZR-75-1/MUC1siRNA cells with CDDP resulted in over 60% apoptosis. The ZR-75-1 cells were also treated with different concentrations of etoposide. The results showed that sensitivity to 10 and 50 µM etoposide was increased substantially by knocking-down MUC1 expression.

To determine if knocking-down MUC1 affects chemosensitivity *in vivo*, mice were injected with ZR-75-1 cells stably expressing the empty viral vector or MUC siRNA. Growth of the ZR-75-1/MUC1siRNA was somewhat slowed compared to that found for ZR-75-1/vector cells. Treatment with CDDP was associated with a partial slowing of ZR-75-1/vector tumor growth (FIG. 12). By contrast, the ZR-75-1/MUC1siRNA tumors were considerably more sensitive to CDDP treatment (FIG. 12).

The present invention has been shown by both description and examples. The Examples are only examples and cannot be construed to limit the scope of the invention. One of ordinary skill in the art will envision equivalents to the inventive process described by the following claims that are within the scope and spirit of the claimed invention.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5

Barry & Sharkey, *Hum. Pathol.*, 16:225-7, 1985.

Baruch *et al.*, *Int. J. Cancer*, 71:741-749, 1997.

Bertrand *et al.*, *Biochem. Biophys. Res. Commun.*, 296:1000-10004, 2002.

Brummelkamp *et al.*, *Science*, 296:550-553, 2002.

10

Brunner *et al.*, *Nature*, 385:829-833, 1997.

Crooke *et al.*, *J. Pharmacol. Exp. Ther.*, 277:923-937, 1996.

Daniels & Reynolds, *Mol. Cell. Biol.*, 19:3614-23, 1999.

Dawson *et al.*, *Science* 266:776, 1994.

Devroe & Silver, *BMC Biotechnol*, 2:15, 2002.

15

Duffy, in *Vaccine Preparation Techniques*, Noyes Data Corporation of Park Ridge, N.J., 1980.

Elbashir *et al.*, *Methods*, 26:199-213, 2002.

Finn *et al.*, *Immunol. Rev.* 145:61-89, 1995.

Fisher *et al.*, *J. Biol. Chem.*, 277:22980-22984, 2002.

Gansow, *Int. J. Rad Appl. Instrum. [B], Nucl. Med. Biol.* 18:369-381, 1991.

20

Goding, In: *Monoclonal Antibodies: Principles and Practice*, 2d ed., Orlando, Fla., Academic Press, pp. 60-61, 1986.

Harborth *et al.*, *J. Cell Sci.*, 114:4557-4565, 2001.

Hohjoh, *FEBS Lett.*, 521:195-199, 2002.

Itzkowitz *et al.*, *Cancer*, 66:1960-6, 1990.

25

Jawhari *et al.*, *J. Pathol.*, 189:180-85, 1999.

Jensen *et al.*, *Bioconjug. Chem.*, 13:975-984, 2002.

Jones *et al.*, *Nature* 321:522-525, 1986.

Kabanov *et al.*, *FEBS Lett.*, 259:327-330, 1990.

Kharbanda *et al.*, *Cancer Res.*, 56:3617-3621, 1996.

30

Kufe *et al.*, *Hybridoma*, 3:223-232, 1984.

Kumar *et al.*, *Mol. Pharmacol.*, 63:276-282, 2003.

- LeBel *et al.*, Chem. Res. Toxicol. 5:227-231, 1992.
- Letsinger *et al.*, Proc. Natl. Acad. Sci. USA, 86:6553-6556, 1989.
- Li *et al.*, Mol Cell Biol., 18:7216-24, 1998.
- Li *et al.*, J. Biol. Chem., 276:6061-64, 2001.
- 5 Li *et al.*, J. Biol Chem, 276:35239-35242, 2001a.
- Li & Kufe, Biochem Biophys. Res. Commun., 281, 440-43, 2001.
- Ligtenburger *et al.*, Cancer Res., 15:2318-2324, 1992.
- Manoharan *et al.*, Ann. N.Y. Acad. Sci., 660:306-309, 1992
- Manoharan *et al.*, Bioorg. Med. Chem. Let., 3:2765-2770, 1993
- 10 Manoharan *et al.*, Bioorg. Med. Chem. Let., 4:1053-1060, 1994.
- Manoharan *et al.*, Tetrahedron Lett., 36:3651-3654; 1995.
- Manoharan *et al.*, Nucleosides & Nucleotides, 14:969-973, 1995.
- Martinez *et al.*, Cell, 110:563-574, 2002.
- Mishra *et al.*, Biochim. Biophys. Acta, 1264:229-237, 1995.
- 15 Molenaar *et al.*, Cell, 86:391-399, 1996.
- Novak & Dedhar, Cell Mol. Life Sci., 523-37, 1999.
- Oberhauser *et al.*, Nucl. Acids Res., 20:533-538, 1992.
- Oehlke *et al.*, Eur. J. Biochem., 269:4025-4032, 2002.
- Olsnes & Pihl, Pharmac. Ther. 25:355-381, 1981.
- 20 Pandey *et al.*, Cancer Res., 55:4000-4003, 1995.
- Pastan *et al.*, Ann. Rev. Biochem. 61:331-354, 1992.
- Paul *et al.*, Nature Biotechnol., 20:505-508, 2002.
- Perey *et al.*, Cancer Res., 52:2563-68, 1992.
- Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113:269-315, Rosenberg and
- 25 Moore eds. Springer-Verlag, New York, 1994.
- Presta, Curr. Op. Struct Biol. 2:593-596, 1992.
- Reddish *et al.*, Cancer Immunol. Immunother., 42:303-9, 1996.
- Reynolds *et al.*, Mol. Cell. Biol. 9:629-38, 1989.
- Reynolds *et al.*, Mol. Cell. Biol., 14:8333-41, 1994.
- 30 Riechmann *et al.*, Nature 332:323-329, 1988.
- Ring *et al.*, Human Genet., 104:326-32, 1999.

- Saison-Behmoaras *et al.*, EMBO J., 10:1111-1118, 1991.
- Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1989.
- Shapiro, Methods, 21:271-279, 2000.
- 5 Shea *et al.*, Nucl. Acids Res., 18:3777-3783, 1990.
- Shimazui *et al.*, Cancer Res., 56:4154-58, 1996.
- Smith & Waterman, Adv. Appl. Math., 2:482-489, 1981.
- Strouss & Decker, Crit. Rev. Biochem. Mol. Biol., 27:57-92, 1992.
- Sui *et al.*, Pro. Nat'l. Acad. Sci. U.S.A., 99:5515-5520, 2002.
- 10 Svinarchuk *et al.*, Biochimie, 75:49-54, 1993.
- Takeichi, Annu. Rev. Biochem., 59:237-52, 1990.
- Thorpe *et al.*, Immunological Rev. 62:119-158, 1982.
- Thorpe *et al.*, Monoclonal Antibodies in Clinical Medicine, pp. 168-190 Academic Press, NY 1982(a).
- 15 Tijsterman *et al.*, 295:694-697, 2002
- Waldmann, Science, 252:1657, 1991.
- Xia *et al.*, Nature Biotechnol., 20:1006-1010, 2002.
- Yamamoto *et al.*, J. Biol. Chem. 272:12492-94, 1997.
- Yang *et al.*, Mol. Cell. Biol., 21:7807-7816, 2001.
- 20 Yin *et al.*, Mol. Cancer Therap., 1:43-48, 2001
- Yu *et al.*, Proc. Nat'l. Acad. Sci. U.S.A., 99:6047-6052, 2002.
- Yuan *et al.*, PNAS, 94:1437-1440, 1997.
- Zamore, Nature Struct. Biol., 8:746-750, 2001.
- Zatsepin *et al.*, Bioconjug. Chem. 13:822-830, 2002.
- 25 Zrihan-Licht, *et al.*, FEBS Let., 356:130-36, 1994.
- U.S. Patent 4,675,382
- U.S. Patent 4,894,443
- U.S. Patent 5,506,343

CLAIMS

1. A double-stranded RNA complex comprising a first RNA sequence of 19 to 23 nucleotides that will hybridize to SEQ ID NO: 19 under stringent conditions and a second
5 RNA sequence of 19 to 23 nucleotides that will hybridize to said first RNA under stringent conditions.
2. The double-stranded RNA complex of claim 1, wherein said first RNA sequence of 19 to 23 nucleotides will hybridize to SEQ ID NO: 20 under stringent conditions.
- 10 3. The double-stranded RNA complex of claim 1, wherein said first and second RNA sequences are separate RNA oligonucleotides.
4. The double-stranded RNA complex of claim 1, wherein said first and second RNA
15 sequences are two portions of a single RNA oligonucleotide.
5. The double-stranded RNA complex of claim 1, wherein said double-stranded RNA complex comprises at least one modified internucleoside linkage.
- 20 6. The double-stranded RNA complex of claim 1, wherein said double-stranded RNA complex comprises at least one modified sugar moiety.
7. A method of inhibiting the expression of MUC1 in a cell that expresses MUC1, comprising contacting said cell with an interfering RNA oligonucleotide, wherein said
25 interfering RNA oligonucleotide will hybridize with SEQ ID NO: 19 under stringent conditions.
8. The method of claim 7, wherein said interfering oligonucleotide will hybridize with SEQ ID NO: 20 under stringent conditions.
- 30 9. The method of claim 7, wherein said interfering RNA oligonucleotide is a first RNA sequence of 19 to 23 nucleotides of a double-stranded RNA complex comprising said

first RNA sequence and a second RNA sequence of 19 to 23 nucleotides, wherein said first RNA sequence will hybridize to said second RNA sequence under stringent conditions

- 5 10. The method of claim 9, wherein said first and second RNA sequences are separate RNA oligonucleotides.
11. The method of claim 9, wherein said first and second RNA sequences are two portions of a single RNA oligonucleotide.
- 10 12. The method of claim 9, wherein said double-stranded RNA complex comprises at least one modified internucleoside linkage.
13. The method of claim 9, wherein said double-stranded RNA complex comprises at least one modified sugar moiety.
- 15 14. The method of claim 7, wherein said cell is a cancer cell.
- 15 15. The method of claim 14, wherein said cancer cell is a skin cancer cell, a prostate cancer cell, a lung cancer cell, a brain cancer cell, a breast cancer cell, an ovarian cancer cell, a cervical cancer cell, a liver cancer cell, a pancreatic cancer cell, a colon cancer cell, a stomach cancer cell or a leukemia cell.
- 20 16. A method of inhibiting the proliferation of a cancer cell that expresses MUC1 comprising contacting said cancer cell with an interfering RNA oligonucleotide, wherein said interfering RNA oligonucleotide will hybridize with SEQ ID NO: 19 under stringent conditions.
- 25 17. The method of claim 16, wherein said interfering RNA oligonucleotide will hybridize with SEQ ID NO: 20 under stringent conditions.
- 30

18. The method of claim 16, wherein said interfering RNA oligonucleotide is a first RNA sequence of 17 to 23 nucleotides of a double-stranded RNA complex comprising said first RNA sequence and a second RNA sequence of 19 to 23 nucleotides, wherein said first RNA sequence will hybridize to said second RNA sequence under stringent conditions
19. The method of claim 18, wherein said first and second RNA sequences are separate RNA oligonucleotides.
20. The method of claim 18, wherein said first and second RNA sequences are two portions of a single RNA oligonucleotide.
21. The method of claim 18, wherein said double-stranded RNA complex comprises at least one modified internucleoside linkage.
22. The method of claim 18, wherein said double-stranded RNA complex comprises at least one modified sugar moiety.
23. The method of claim 16, wherein said cancer cell is a skin cancer cell, a prostate cancer cell, a lung cancer cell, a brain cancer cell, a breast cancer cell, an ovarian cancer cell, a cervical cancer cell, a liver cancer cell, a pancreatic cancer cell, a colon cancer cell, a stomach cancer cell or a leukemia cell.
24. A method of increasing the sensitivity of a MUC1 expressing cancer cell comprising contacting said cancer cell with an interfering RNA oligonucleotide, wherein said interfering RNA oligonucleotide will hybridize with SEQ ID NO: 19 under stringent conditions.
25. The method of claim 24, wherein said interfering RNA oligonucleotide will hybridize with SEQ ID NO: 20 under stringent conditions.

26. The method of claim 24, wherein said interfering RNA oligonucleotide is a first RNA sequence of 17 to 23 nucleotides of a double-stranded RNA complex comprising said first RNA sequence and a second RNA sequence of 19 to 23 nucleotides, wherein said first RNA sequence will hybridize to said second RNA sequence under stringent conditions
27. The method of claim 26, wherein said first and second RNA sequences are separate RNA oligonucleotides.
28. The method of claim 26, wherein said first and second RNA sequences are two portions of a single RNA oligonucleotide.
29. The method of claim 25, wherein said double-stranded RNA complex comprises at least one modified internucleoside linkage.
30. The method of claim 25, wherein said double-stranded RNA complex comprises at least one modified sugar moiety.
31. The method of claim 24, wherein said cancer cell is a skin cancer cell, a prostate cancer cell, a lung cancer cell, a brain cancer cell, a breast cancer cell, an ovarian cancer cell, a cervical cancer cell, a liver cancer cell, a pancreatic cancer cell, a colon cancer cell, a stomach cancer cell or a leukemia cell.
32. An interfering RNA composition wherein said RNA interfering composition comprises an RNA oligonucleotide of about 17 to about 50 bases wherein said RNA oligonucleotide will inhibit the expression of MUC1 in a cell that expresses MUC1 when said interfering RNA oligonucleotide is administered to said cell in an effective amount.




FIG. 1




FIG. 2




FIG. 3





FIG. 4





FIG. 5

**FIG. 6**




FIG. 7





FIG. 8



Structure and sequence of MUC1 siRNA expression plasmid (pU6-MUC1siRNA#2)

FIG. 9




FIG. 10




FIG. 11




FIG. 12

SEQUENCE LISTING

<110> Kufe, Donald W.
Kharbanda, Surender
Weitman, Steven D.

<120> MUC1 INTERFERENCE RNA COMPOSITIONS AND METHODS DERIVED THEREFROM

<130> ILEX:092WO

<140> 10/447,839

<141> 2003-05-29

<150> 10/293,391

<151> 2002-11-13

<150> 09/951,938

<151> 2001-09-11

<150> 60/231,841

<151> 2000-09-11

<160> 111

<170> PatentIn version 3.2

<210> 1

<211> 45

<212> PRT

<213> Homo Sapien

<400> 1

Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr
1 5 10 15

Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser
20 25 30

Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly
35 40 45

<210> 2

<211> 426

<212> PRT

<213> Homo Sapien

<400> 2

Met Arg Gln Val Cys Cys Ser Ala Leu Pro Pro Pro Pro Leu Glu Lys
1 5 10 15

Gly Arg Cys Ser Ser Tyr Ser Asp Ser Ser Ser Ser Ser Ser Glu Arg
20 25 30

Ser Ser Ser Ser Ser Ser Ser Ser Ser Glu Ser Gly Ser Ser Ser Arg
35 40 45

Ser Ser Ser Asn Asn Ser Ser Ile Ser Arg Pro Ala Ala Pro Pro Glu

50		55		60
Pro Arg Pro Gln Gln Gln Pro Gln Pro Arg Ser Pro Ala Ala Arg Arg				
65		70		75 80
Ala Ala Ala Arg Ser Arg Ala Ala Ala Ala Gly Gly Met Arg Arg Asp				
	85		90	95
Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val Ser Leu Ala Cys				
	100		105	110
Tyr Ser Pro Ser Leu Lys Ser Val Gln Asp Gln Ala Tyr Lys Ala Pro				
	115		120	125
Val Val Val Glu Gly Lys Val Gln Gly Leu Val Pro Ala Gly Gly Ser				
	130		135	140
Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly Arg Val Ala Leu				
145		150		155 160
Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly Gly Leu Gln Arg				
	165		170	175
Glu Gln Val Ile Ser Val Gly Ser Cys Val Pro Leu Glu Arg Asn Gln				
	180		185	190
Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gln Pro Leu Val Phe Lys				
	195		200	205
Thr Ala Phe Ala Pro Leu Asp Thr Asn Gly Lys Asn Leu Lys Lys Glu				
	210		215	220
Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg Pro Lys Leu Lys				
225		230		235 240
Lys Met Lys Ser Gln Thr Gly Gln Val Gly Glu Lys Gln Ser Leu Lys				
	245		250	255
Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys				
	260		265	270
Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly				
	275		280	285
Asn Gly Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys Val Lys Val Glu				
	290		295	300

Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp
 305 310 315 320

Thr Val Arg Gly Arg Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser
 325 330 335

Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr
 340 345 350

Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu
 355 360 365

Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys
 370 375 380

Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln Ser Val Leu Trp
 385 390 395 400

Asp Thr Pro Gly Thr Gly Val Ser Ser Ser Gln Trp Ser Thr Ser Pro
 405 410 415

Lys Pro Arg Ser Cys Thr Arg Arg Gly Ser
 420 425

<210> 3
 <211> 422
 <212> PRT
 <213> Homo Sapien

<400> 3

Met Arg Gln Val Cys Cys Ser Ala Leu Pro Pro Pro Pro Leu Glu Lys
 1 5 10 15

Gly Arg Cys Ser Ser Tyr Ser Asp Ser Ser Ser Ser Ser Ser Glu Arg
 20 25 30

Ser Ser Ser Ser Ser Ser Ser Ser Ser Glu Ser Gly Ser Ser Ser Arg
 35 40 45

Ser Ser Ser Asn Asn Ser Ser Ile Ser Arg Pro Ala Ala Pro Pro Glu
 50 55 60

Pro Arg Pro Gln Gln Gln Pro Gln Pro Arg Ser Pro Ala Ala Arg Arg
 65 70 75 80

Ala Ala Ala Arg Ser Arg Ala Ala Ala Ala Gly Gly Met Arg Arg Asp
 85 90 95

Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val Ser Leu Ala Cys
 100 105 110

Tyr Ser Pro Ser Leu Lys Ser Val Gln Asp Gln Ala Tyr Lys Ala Pro
 115 120 125

Val Val Val Glu Gly Lys Val Gln Gly Leu Val Pro Ala Gly Gly Ser
 130 135 140

Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly Arg Val Ala Leu
 145 150 155 160

Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly Gly Leu Gln Arg
 165 170 175

Glu Gln Val Ile Ser Val Gly Ser Cys Val Pro Leu Glu Arg Asn Gln
 180 185 190

Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gln Pro Leu Val Phe Lys
 195 200 205

Thr Ala Phe Ala Pro Leu Asp Thr Asn Gly Lys Asn Leu Lys Lys Glu
 210 215 220

Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg Pro Lys Leu Lys
 225 230 235 240

Lys Met Lys Ser Gln Thr Gly Gln Val Gly Glu Lys Gln Ser Leu Lys
 245 250 255

Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr Arg Trp Phe Lys
 260 265 270

Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg Ile Lys Tyr Gly
 275 280 285

Asn Gly Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys Val Lys Val Glu
 290 295 300

Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp
 305 310 315 320

Thr Val Arg Gly Arg Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser
 325 330 335

Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr
 340 345 350

Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gln Leu
 355 360 365

Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys
 370 375 380

Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gln Ser Val Leu Trp
 385 390 395 400

Asp Thr Pro Gly Thr Gly Val Ser Ser Ser Gln Trp Ser Thr Ser Pro
 405 410 415

Ser Thr Leu Asp Leu Asn
 420

<210> 4
 <211> 17
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 4

His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser
 1 5 10 15

Cys

<210> 5
 <211> 16
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 5

His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser
 1 5 10 15

<210> 6
 <211> 17
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 6

Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp
1 5 10 15

Cys

<210> 7
<211> 19
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 7

Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser
1 5 10 15

Gly Ala Cys

<210> 8
<211> 19
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 8

Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg
1 5 10 15

Tyr Asn Leu

<210> 9
<211> 20
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 9

Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu Ala
1 5 10 15

Phe Arg Glu Cys
20

<210> 10

<211> 1054
 <212> DNA
 <213> Homo Sapien

<400> 10
 ccctgcagaa gccgcgctcc ctactcggtc cgggggcaga gggggcgca gagagcaagt 60
 gggcgggcgt cccatcctcc gcacccctcc ccaggtcctg gcgcacaggg tgggagcgt 120
 gcgctgcgcc gcgctgcgca tcgcggcccg cttgccgcct gcccctgcc ctagctgggc 180
 cacctccccg ggctgcgggt ggagggctaa gaggcgctaa cgttacgctg tttccggttt 240
 tccagcgggc tctgtttccc ctcccaaggc ggcggcggct gagcggcgga gcccccaaa 300
 tggcctggcc agatgcggca ggtttgctgc tcagcgtgc cgccgccgc actggagaag 360
 ggtcggtgca gcagctacag cgacagcagc agcagcagca gcgagaggag cagcagcagc 420
 agcagcagca gcagcgagag cggcagcagc agcaggagca gcagcaacaa cagcagcatc 480
 tctcgtcccg ctgcgcccc agagccgcgg ccgcagcaac agccgcagcc ccgcagcccc 540
 gcagcccga gagccgccgc ccgttcgca gccgcagccg ccggcgccat gaggcggcagc 600
 ccggcccccg gcttctccat gctgctcttc ggtgtgtgc tcgctgcta ctgcgccagc 660
 ctcaagtcag tgcaggacca ggcgtacaag gcacccgtgg tggaggagg caaggtacag 720
 gggctggtcc cagccggcgg ctccagctcc aacagcacc gagagccgcc cgctcggtt 780
 cgggtggcgt tggtaaaggt gctggacaag tggccgctcc ggagcgggg gctgcagcgc 840
 gagcaggtga tcagcgtggg ctctgtgtg ccgctcgaaa ggaaccagcg ctacatcttt 900
 ttcctggagc ccacggaaca gcccttagtc ttttaagacgg cctttgcccc cctcgatacc 960
 aacggcaaaa atctcaagaa agaggtgggc aagatcctgt gactgactg cggtagtgc 1020
 cccctccct ttgctggaga aaggggggag gggc 1054

<210> 11
 <211> 419
 <212> DNA
 <213> Homo Sapien

<400> 11
 gcactgcccc taccaccacc gtgctcacct acctgccttg taaccacag ccaccggcc 60
 caagttgaag aagatgaaga gccagacggg acaggtgggt gagaagcaat cgctgaagt 120
 tgaggcagca gccggaatc ccagccttc ctaccgttg ttcaaggatg gcaaggagct 180
 caaccgcagc cgagacattc gcatcaaata tggcaacggc aggtaagcaa tatccagcct 240
 gtccctccatc caagcagctg cctccctcc tctcgagaag gagtggcctg aactgggcag 300
 aggccagggc tgtgccccca gactcaccca tggaaccagt ccagccct ctccatactc 360
 ccttccttg cactcccag ccttcttct gcagctcggg gaccctctgg tcatggtg 419

<210> 12
 <211> 493
 <212> DNA
 <213> Homo Sapien

<400> 12
 gccactagtc ctgccctgtg ttgtcctaag ggcccaaggc tccctgcagc tgcagggact 60
 ccgtgccccca cctggactcc agaaattgct ggggggaggg aatctccttc ccatctaagc 120
 tgcagggcca ctgtggctct gtggagagag gcaaccgctg ggtgactgct ggggagccac 180
 agccggccct ggctcacgcc tctccccctt ttatcccctc cctaaccaga aagaactcac 240
 gactacagtt caacaagggtg aagggtggagg acgctgggga gtatgtctgc gaggccgaga 300
 acatcctggg gaaggacacc gtccggggcc ggctttacgt caacagcggg aggtgggccc 360
 agacagaggg aagggtccta gaggggtttg gcagggcggg ccagtggccc ccagccctt 420
 ggggcctgca tgtgatccat ctgcactca actcccctcc ctctgctgc tgccatatca 480
 agccctagat ctc 493

<210> 13
 <211> 350
 <212> DNA
 <213> Homo Sapien

<400> 13
 ggtcatcttc cagttttgac gtggggcatg aaggagatga ttcctggggc ctagggatag 60
 tctcagtgcg tcaactggcac atgtctctca taccctcagt gagcaccacc ctgtcatcct 120
 ggtcggggca cgcccgaag tgcaacgaga cagccaagtc ctattgcgtc aatggaggcg 180
 tctgctacta catcgagggc atcaaccagc tctcctgcaa gtaagtgacc agtaggggtg 240
 ggcattgggag caagaacagg gtaggagatg ctgggtcaga agtggagggc tctaggaaaa 300
 gaggggtcca agccactgac aagagggtccc caaggggtgt agacaggaag 350

<210> 14
 <211> 326
 <212> DNA
 <213> Homo Sapien

<400> 14
 aagtgcctga cttgggtttt ctcatcctac actgtgcact ttgatttcta accttagcct 60
 cgcggatgat gccagtttgt tctgtgattt tcccccttt ccttctccag atgtccaaat 120
 ggattctttcg gacagagatg tttggagaaa ctgcctttgc gattgtacat gccagatcct 180
 aagcaaagta tgtttgaaga tacaacaca agtccttgct ccttagaaag cttctgggtg 240
 cagtcccccc aatgtagggc atagggccag ggggtgttggg tgttttgatc tttggctgtt 300
 ttgttttgtt tctcttttct tttttg 326

<210> 15
 <211> 310
 <212> DNA
 <213> Homo Sapien

<400> 15
 aatacaaatg gtaacgggtgg caaggaaccc agctggcatt ggcaggagcc cgtgccgggg 60
 tggttgaatg cctgtgtctt gctatcctgg ctctctcttt ctggttttct ttcttttggg 120
 aggtgtcctg tgggatacac cggggacagg tgtcagcagt tcgcaatggg caacttctcc 180
 agtatgtctc tttcttctat ttcttctctt ccctgggtgac tgacagtctc cccctgggga 240
 gggatggggc cttgcttagc aagactaggg ggagatgtag aggggtgcct gcgctcctta 300
 gaggagacgg 310

<210> 16
 <211> 259
 <212> DNA
 <213> Homo Sapien

<400> 16
 ggatggaaag gagctgggca ggacctgagc tggggagagc ctatggcttt gggggcaaag 60
 ggggtctctgc accactatcc ctatgggggtt tgctcctgc cccaccctc acatctaccc 120
 tacctctgca gaagccgagg agctgtacca gaagagggtc ctgaccatca cgggcatctg 180
 cgtggctctg ctggctcgtg gcctcgtctg tgtgggtggc tactgcaaga ccaagtgagt 240
 gtcactcact caagctggg 259

<210> 17
 <211> 258
 <212> DNA
 <213> Homo Sapien

<400> 17
 ttgtgaccct cgctcttctg cactgccaga gcaccttgga tttgaattaa agggatatgaa 60
 acctctgtgt gtcactcagc accatctgcg tggccctctt ccacagcctc cgatgccatg 120
 tgtgctgaat gtttggtttc ctttccaaaa aatggaaaag ggatgattcc aaaaatctct 180
 cctggcccca tcgagatgtc ctatcataaa ctacgttgat ttagcaggag acgaaagaag 240
 ctcatgaaca gaagggca 258

<210> 18
 <211> 8181
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (6890)..(7960)
 <223> definition of "n" in this sequence is unavailable at this time

<220>

<221> misc_feature

<222> (6890)..(7960)

<223> unknown nucleotide

<400> 18

```

gaattcagaa ttttagaccc tttggccttg ggggtccatcc tggagaccct gaggtctaag      60
ctacagcccc tcagccaacc acagaccctt ctctggctcc caaaaggagt tcagtcccag      120
aggggtggtca cccacccttc agggatgaga agttttcaag ggggtattact caggcactaa      180
ccccaggaaa gatgacagca cattgccata aagttttggt tgttttctaa gccagtgcaa      240
ctgcttatttt tagggatttt ccgggatagg gtggggaagt ggaaggaatc ggcgagtaga      300
agagaaagcc tgggaggggtg gaagttaggg atctagggga agtttggctg atttggggat      360
gcgggtgggg gaggtgctgg atggagttaa gtgaaggata ggggtgcctga gggaggatgc      420
ccgaagtcct cccagaccca cttactcacg gtggcagcgg cgacactcca gtctatcaaa      480
gatccgccgg gatggagagc caggaggcgg gggctgcccc tgaggtagcg gggaggccgg      540
ggggccgggg ggcggacggg acgagtgcaa tattggcggg ggaaaaaaca aactgcacc      600
gcgtcccgtc cctcccgccc gcccgggccc ggatcccgtc cccaccgcc tgaagccggc      660
ccgaccggga acccgggccg ctggggagtt ggggtcacct tggaggccag agagacttgg      720
cgcccggaag caaagggaat ggcaaggggg aggggggagg gagaacggga gtttgcgag      780
tccagaaggc cgctttccga cgccggggcg ttgcgcgcgc ttgctcttta agtactcaga      840
ctgcgcggcg cgagccgtcc gcatggtgac gcgtgtccca gcaaccgaac tgaatggctg      900
ttgcttgcca atgccgggag ttgaggtttg gggccgcccc cctagctact cgtgttttct      960
ccggcctgcg agttgggggg ctcccgccct cccggcccgc tcctggggcg gctgacgtca     1020
gatgtcccca cccgcccag cgcctgcccc aagggtctcg ccgcacacaa agctcggcct     1080
cgggcgcggg cgcgcgggcg agagcggtag tctctgcct gctgatctga tgcgctccaa     1140
tcccgtgcct cgccgaagtg tttttaaaagt gttctttcca acctgtgtct ttggggctga     1200
gaactgtttt ctgaatacag gcggaactgc ttccgtcggc ctagaggcac gctgcgactg     1260
cgggacccaa gttccacgtg ctgcccgggc ctgggatagc ttcctcccct cgtgcactgc     1320
tgccgcacac acctcttggc tgtcgcgcac tacgcacctc acgtgtgctt ttgcccccg     1380
ctacgtgcct acctgtcccc aataaccact tgctcccaa aggatagttc tgtgtccgta     1440
aatcccattc tgtcacccca cctactctct gccccccct tttttgtttt gagacggagc     1500
tttgctctgt cgcccaggct ggagtgcaat ggcgcgatct cggctcactg caacctccgc     1560
ctcccggggt caagcgattc tcctgcctca gcctcctgag tagctggggg tacagcgccc     1620
gccaccacgc tcggctaatt tttgtagttt ttagtagaga cgaggtttca ccatcttggc     1680

```

caggctggtc	ttgaacccct	gaccttgtga	tccactcgcc	tcggccttcc	aaagtgttgg	1740
gattacgggc	gtgacgaccg	tgccacgcat	ctgcctctta	agtacataac	ggcccacaca	1800
gaacgtgtcc	aactcccccg	cccacgttcc	aacgtcctct	cccacatacc	tcggtgcccc	1860
ttccacatac	ctcaggaccc	cacccgctta	gctccatttc	ctccagacgc	caccaccacg	1920
cgtcccggag	tgccccctcc	taaagctccc	agccgtccac	catgctgtgc	gttcctccct	1980
ccctggccac	ggcagtgacc	cttctctccc	gggccttget	tccctctcgc	gggctctgct	2040
gcctcactta	ggcagcgctg	cccttactcc	tctccgcccc	gtccgagcgg	cccctcagct	2100
tcggcgccca	gccccgcaag	gctcccgggt	accactagag	ggcgggagga	gctcctggcc	2160
agtgggtggag	agtggcaagg	aaggacccta	gggttcatcg	gagcccaggt	ttactccctt	2220
aagtggaaat	ttcttccccc	actcctcctt	ggctttctcc	aaggagggaa	cccaggctgc	2280
tggaaagtcc	ggctgggggg	gggactgtgg	gttcagggga	gaacgggggtg	tggaaacggga	2340
cagggagcgg	ttagaagggg	ggggctattc	cgggaagtgg	tggggggagg	gagcccaaaa	2400
ctagcaccta	gtccactcat	tatccagccc	tcttatttct	cggccgctct	gcttcagtgg	2460
acccggggag	ggcggggaag	tggagtggga	gacctagggg	tgggcttccc	gaccttgctg	2520
tacaggacct	cgacctagct	ggctttgttc	cccatcccca	cgtaggttgt	tgccctgagg	2580
ctaaaactag	agcccagggg	ccccagttc	cagactgccc	ctccccctc	ccccggagcc	2640
agggagtggg	tggtgaaagg	gggaggccag	ctggagaaca	aacgggtagt	caggggggtg	2700
agcgattaga	gcccttgtag	cctaccagag	aatggttggg	gaggaggagg	aagaggtagg	2760
aggtagggga	gggggcgggg	ttttgtcacc	tgtcacctgc	tcgctgtgcc	tagggcgggc	2820
gggcggggag	tggggggacc	ggtataaagc	ggtaggcgcc	tgtgcccgtc	ccacctctca	2880
agcagccagc	gcctgcctga	atctgttctg	ccccctcccc	accatttca	ccaccaccat	2940
gacacggggc	accagttctc	ctttcttctc	gctgctgctc	ctcacagtgc	ttacagggtga	3000
ggggcacgag	gtggggagtg	ggctgccctg	cttaggtggg	cttcgtgggc	tttctgtggg	3060
ttttgtctcc	tggcagatgg	caccatgaag	ttaaggtaag	aattgcagac	agaggctgcc	3120
ctgtctgtgc	cagaaggagg	gagaggctaa	ggacaggctg	agaagagttg	cccccaacc	3180
tgagagtggg	taccaggggc	aagcaaagt	cctgtagaga	agtctagggg	gaagagagta	3240
gggagagggg	aggcttaaga	ggggaagaaa	tgcaggggcc	atgagccaag	gcctatgggc	3300
agagagaagg	aggctgctgc	agggaaggag	gcttccaacc	caggggttac	tgaggctgcc	3360
cactccccag	tcctcctggg	attatttctc	tggtggccag	agcttatatt	ttcttcttgc	3420
tcttattttt	ccttcataaa	gacccaaccc	tatgacttta	acttcttaca	gctaccacag	3480
cccctaaacc	cgcaacagtt	gttacagggt	ctggtcatgc	aagctctacc	ccagggtggg	3540
aaaaggagac	ttcggctacc	cagagaaggt	cagtgcccg	ctctactgag	aagaatgctg	3600

tgagtatgac	cagcagcgta	ctctccagcc	acagccccgg	ttcagggtcc	tccaccactc	3660
agggacagga	tgctactctg	gccccggcca	cggaaccagc	ttcagggtca	gctgccacct	3720
ggggacagga	tgctacctcg	gtcccagtca	ccaggccagc	cctggggtcc	accaccccg	3780
cagcccacga	tgctacctca	gccccggaca	acaagccagc	cccggggtcc	accgcccccc	3840
cagcccacgg	tgctacctcg	gccccggaca	ccaggccggc	cccggggtcc	accgcccccc	3900
cagcccattg	tgctacctcg	gccccggaca	acaggccccg	cttggggtcc	accgccccct	3960
cagtccacaa	tgctacctcg	gcctcaggct	ctgcatcagg	ctcagcttct	actctgggtg	4020
acaacggcac	ctctgccagg	gctaccacaa	ccccagccag	caagagcact	ccattctcaa	4080
ttcccagcca	ccactctgat	actcctacca	cccttgccag	ccatagcacc	aagactgatg	4140
ccagtagcac	tcaccatagc	acggtacctc	ctctcacctc	ctccaatcac	agcacttctc	4200
cccagttgtc	tactgggggtc	tctttctttt	tctgtctttt	tcacatttca	aacctccagt	4260
ttaattcctc	tctggaagat	cccagcaccg	actactacca	agagctgcag	agagacattt	4320
ctgaaatggt	gagtatcggc	ctttccttcc	ccatgctccc	ctgaagcagc	catcagaact	4380
gtccacaccc	tttgcacaa	gcccaggtcc	tttccctctc	accccagttt	ttgcagattt	4440
ataaacaagg	gggttttctg	ggcctctcca	atattaagtt	caggtacagt	tctgggtgtg	4500
gaccagtggt	ggtggttgga	gggttggggtg	gtggtcatga	ccgtaggagg	gactggtgca	4560
cttaagggtg	ggggaagagt	gctgagccag	agctgggacc	cgtgggtgaa	gtgcccattt	4620
ccctgtgacc	aggccaggat	ctgtggtggt	acaattgact	ctggccttcc	gagaaggtag	4680
catcaatgtc	cacgacgtgg	agacacagtt	caatcagtat	aaaacggaag	cagcctctcg	4740
atataacctg	acgatctcag	acgtcagcgg	tgaggctact	tccctggctg	cagccagcac	4800
catgccgggg	cccctctcct	tccagtgtct	gggtccccgc	tctttcctta	gtgctggcag	4860
cgggaggggg	gcctcctctg	ggagactgcc	ctgaccactg	cttttccttt	tagtgagtga	4920
tgtgccattt	cctttctctg	cccagtctgg	ggctgggggtg	ccaggctggg	gcatcgcgct	4980
gctggtgctg	gtctgtgttc	tggttgcgct	ggccattgtc	tatctcattg	ccttgggtgag	5040
tgcagtcctc	ggccctgatc	agagcccccc	ggtagaaggc	actccatggc	ctgccataac	5100
ctcctatctc	cccaggctgt	ctgtcagtgc	cgccgaaaga	actacgggca	gctggacatc	5160
tttccagccc	gggataccta	ccatcctatg	agcgagtacc	ccacctacca	cacccatggg	5220
cgctatgtgc	cccctagcag	taccgatcgt	agcccctatg	agaagggtgag	attgggcccc	5280
acaggccagg	ggaagcagag	ggtttggtctg	ggcaaggatt	ctgaaggggg	tacttgga	5340
acccaaagag	cttggaagag	gtgagaagtg	gcgtgaagtg	agcagggggag	ggcctggcaa	5400
ggatgagggg	cagaggtcag	aggagttttg	ggggacaggc	ctgggaggag	actatggaag	5460

aaaggggccc	tcaagaggga	gtggccccac	tgccagaatt	cctaaaagat	cattggccgt	5520
ccacattcat	gctggctggc	gctggctgaa	ctggtgccac	cgtggcagtt	ttgttttgtt	5580
ttgctttttt	gcacccagag	gcaaaatggg	tggagcacta	tgcccagggg	agcccttccc	5640
gaggagtccc	aggggtgagc	ctctgtgccc	ctaatacatc	cctaggaatg	gagggtagac	5700
cgagaaaggc	tggcataggg	ggaggtttcc	caggtagaag	caagaagaag	tgtcagcaga	5760
ccagggtgagc	gtgggtgcca	gtggggttct	tgggagcttc	aaggaagcaa	ggaacgctcc	5820
ctccttcctc	tcctggctct	tctctatggg	acctagtaaa	taattactgc	agccacctga	5880
ggctggaaaa	ccactccagg	tgggggagga	gagagtttag	ttttcttgct	cctattttcc	5940
tcctcctgga	gacctccctc	tctcggtttt	acaaagacac	agatacacc	cgccccccaa	6000
aacacacaca	cacacacaca	cacacacacc	tccttaggct	ggaacagcag	agaatggagg	6060
gacaaggggg	ctgattagag	ccaagaagag	ggagtgaagg	agagcagagg	gaggagggca	6120
gccctgttta	cagtcacctg	gctgggtggg	tggcaggtgc	tctctctgaa	ttaacccttt	6180
gagagctggc	caggactctg	gactgattac	cccagcctgg	ggtggcatcc	aggggctcta	6240
ggaggtacct	tttgctcctc	accctggatc	tcttttcctt	ccaccaggt	ttctgcaggt	6300
aatggtggca	gcagcctctc	ttacacaaac	ccagcagtgg	cagccacttc	tgccaacttg	6360
taggggcacg	tcgcccgtg	agctgagtgg	ccagccagtg	ccattccact	ccactcaggt	6420
tcttcagggc	cagagcccct	gcaccctgtt	tgggctgggt	agctgggagt	tcaggtgggc	6480
tgtcacacg	tccttcagag	gccccaccaa	tttctcggac	acttctcagt	gtgtggaagc	6540
tcattgtggc	ccctgaggct	catgcctggg	aagtgttggt	gtgggggctc	ccaggaggac	6600
tggcccagag	agccctgaga	tagcggggat	cctgaactgg	actgaataaa	acgtggtctc	6660
ccactggcgc	caacttctga	tctttcatct	gtgaccctg	ggcagcaggg	cgtcagaatg	6720
tgtgtgaggg	ggctggggga	ggagacaggg	aggccaggag	gcagtaagga	gcgagtttgt	6780
ttgagaagca	ggagatgtga	ggaggaggtg	acattgggga	gtaggggtgg	cctgaggagc	6840
cacctctggc	taaccctggc	agcacaagag	gaaggaggaa	acgaaaccca	ggcnggcttt	6900
ggagggctag	cgtgactggg	ctccgtgact	gagctctgtg	tgccagtggc	tctcccctct	6960
cctcgcctgg	cccacgccct	ccttgcccct	ggcatggtgc	cccccaggtg	gctctattct	7020
tagctgtccg	ggtgtgaagt	aaatccttgg	gcagtataaa	cagcccagag	tcaacagggt	7080
tgagataagc	agaggctggg	tcagatccgg	gcgctggcac	caggcccagc	cccctccctg	7140
accccggtcn	ccccaccagc	ctgctgcccc	tggggtggn	tcacaacac	cctgggaatg	7200
gggaagtgg	tctggttccc	tgaccctttt	ggcccaggca	cgttgccctg	ccctcgaccg	7260
cattccccca	gggcctgtgc	tgcaggcctg	gaagccctga	ttggggcctg	ccaccagcag	7320
ccagagagct	atgttccctg	gcagctgtga	tgcgctcagg	ccgggccagg	acacgtgtgg	7380

caggaggctt agagcacctg cctggggcct tcctctctca ggcaccagat ccattggttg	7440
ctcctgccta gaaccacagc ctagcacccc tgctccctcc cgcctaccac acccagcaca	7500
gaaactcaca ggaatgattg cgctcagga aggcagagat gtgcctggca tcacagttta	7560
ttgtttataa accatgacaa taacagctgt tgctcagcac aggcctagca gagccactg	7620
cagggggacg gcagcgggca ccagaggcct tgctggccc aaccaatgg gaacacccag	7680
actcagctgg gtccccaagg gagacttggc acattggcat ggggtgtggga caggtaaagc	7740
atgcaagagg gagaagagg acataagggg catgcggctg cggggtgttg ggacccaaat	7800
aaataaagca ggatgacagg gtccccttcc cctcaccagg aatgcctgac agcgtccagc	7860
cccaaagcct gcctgtcca aggctgtagt tcagcatcaa cagggcaggg agcttggcag	7920
ggcaagggca gagctggaga tcatgccag tnttccaggt gccctccctc ccaatcagcc	7980
tggggggcac aggacagga tggagaagg gctctctcca tggcttgggt aacatgccaa	8040
aggcaggtca tagggcagac tcagtggggg tgggggcctg gctaacaagc aatggagaga	8100
acgggggcca tccagagagg ttggcagaag agagcccctg ggtcaagaga aaactttggg	8160
gaagacaaga cacgggagaa g	8181

<210> 19
 <211> 1799
 <212> RNA
 <213> RNA

<400> 19	
ccaccucuca agcagccagc gccugccuga aucuguucug ccccccuccc acccauuuca	.60
ccaccaccau gacaccgggc acccagucuc cuuucuuccu gcugcugcuc cucacagugc	120
uuacaguugu uacagguucu ggucaugcaa gcucuacccc agguggagaa aaggagacuu	180
cggcuaccca gagaaguuca gugcccagcu cuacugagaa gaaugcugug aguaugacca	240
gcagcguacu cuccagccac agccccgguu caggcuccuc caccacucag ggacaggau	300
ucacucuggc cccggccacg gaaccagcuu cagguucagc ugccaccugg ggacaggau	360
ucaccucggu cccagucacc aggccagccc ugggcuccac ccccccgcca gccacgaug	420
ucaccucagc cccggacaac aagccagccc cgggcuccac cccccccca gccacggug	480
ucaccucggc cccggacacc aggccggccc cgggcuccac cccccccca gccauggug	540
ucaccucggc cccggacaac aggcccgcgu ugggcuccac cggccucca guccacaug	600
ucaccucggc cucaggcucu gcaucaggcu cagcuucuac ucuggugcac aacggcaccu	660
cugccagggc uaccacaacc ccagccagca agagcacucc auucucauu cccagccacc	720
acucugauac uccuaccacc cuugccagcc auagcaccaa gacugaugcc aguagcacuc	780
accuagcac gguaccuccu cucaccuccu ccauacacag cacuuccucc caguugucua	840

cugggggucuc	uuucuuuuuc	cugucuuuuc	acauuucaaa	ccuccaguuu	aauuccucuc	900
uggaagaucc	cagcaccgac	uacuaccaag	agcugcagag	agacauuucu	gaaauguuuu	960
ugcagauuua	uaaacaaggg	gguuuucugg	gccucuccaa	uauuaaguuc	aggccaggau	1020
cugugguggu	acaauugacu	cuggccuucc	gagaagguac	caucaauguc	cacgacgugg	1080
agacacaguu	caaucaguau	aaaacggaag	cagccucucg	auauaaccug	acgaucucag	1140
acgucagcgu	gagugaugug	ccauuuccuu	ucucugccca	gucuggggcu	ggggugccag	1200
gcuggggcau	cgcgcugcug	gugcuggucu	guguucuggu	ugcgcuggcc	auugucuauc	1260
ucauugccuu	ggcugucugu	cagugccgcc	gaaagaacua	cgggcagcug	gacaucuuuc	1320
cagcccggga	uaccuaccu	ccuaugagcg	aguacccac	cuaccacacc	caugggcgcu	1380
augugcccc	uagcaguacc	gaucguagcc	ccuaugagaa	gguuucugca	gguaauggug	1440
gcagcagccu	cucuacaca	aaccagcag	uggcagccac	uucugccaac	uuguaggggc	1500
acgucgccc	cugagcugag	uggccagcca	gugccauucc	acuccacuca	gguuucucag	1560
ggccagagcc	ccugcacccu	guuugggcug	gugagcuggg	aguucaggug	ggcugcucac	1620
acguccuua	gaggccccac	caauuucucg	gacacuucuc	agugugugga	agcucaugug	1680
ggccccugag	gcucaugccu	gggaaguguu	gugguggggg	cucccaggag	gacuggccca	1740
gagagcccug	agauagcggg	gauccugaac	uggacugaau	aaaacguggu	cucccacug	1799

<210> 20
 <211> 1428
 <212> RNA
 <213> RNA

<400> 20	
augacaccgg	gcaccaguc uccuuucuu cugcugcugc uccucacagu gcuuacaguu 60
guuacagguu	cuggucaugc aagcucuaac ccagguggag aaaaggagac uucggcuacc 120
cagagaaguu	cagugcccag cucuacugag aagaauugcug ugaguaugac cagcagcgua 180
cucuccagcc	acagccccgg uucaggcucc uccaccacuc agggacagga ugucacucug 240
gccccggcca	cgggaaccagc uucagguuca gcugccaccu ggggacagga ugucaccucg 300
gucccaguca	ccaggccagc ccugggcucc accaccccg cagcccacga ugucaccuca 360
gccccggaca	acaagccagc cccgggcucc accgcccccc cagcccacgg ugucaccucg 420
gccccggaca	ccaggccggc cccgggcucc accgcccccc cagcccagg ugucaccucg 480
gccccggaca	acaggccccg cuugggcucc accgccccuc caguaccaca ugucaccucg 540
gccucaggcu	cugcaucagg cucagcuucu acucuggugc acaacggcac cucugccagg 600
gcuaccacaa	ccccagccag caagagcacu ccuauucuaa uucccagcca ccacucugau 660
acuccuacca	cccuugccag ccuauagcacc aagacugaug ccaguagcac ucaccuagc 720

```

acgguaccuc cucucaccuc cuccaauac agcacuucuc cccaguuguc uacugggguc 780
ucuuucuuuu uccugucuuu ucacauuua aaccuccagu uuaauuccuc ucuggaagau 840
cccagcaccg acuacuacca agagcugcag agagacauuu cugaaauguu uuugcagauu 900
uauaaacaag gggguuuucu gggccucucc aaauuaagu ucaggccagg aucuguggug 960
guacaauuga cucuggccuu ccgagaaggu accaucaaug uccacgacgu ggagacacag 1020
uucaaucagu auaaaacgga agcagccucu cgauauaacc ugacgaucuc agacgucagc 1080
gugagugaug ugccauuucc uuucucugcc cagucugggg cuggggugcc aggcuggggc 1140
aucgcgcugc uggugcuggu cuguguucug guugcgcugg ccuugucua ucucauugcc 1200
uuggcugucu gucagugccg ccgaaagaac uacgggcagc uggacaucuu uccagcccgg 1260
gauaccuacc auccuaugag cgaguacccc accuaccaca cccaugggcg cuaugugccc 1320
ccuagcagua ccgaucguag ccccuauagag aagguuucug cagguaaugg uggcagcagc 1380
cucucuuaa caaacccagc aguggcagcc acuucugcca acuuguag 1428

```

```

<210> 21
<211> 21
<212> DNA
<213> ARTIFICIAL

```

```

<220>
<223> Target MUC1 RNA Sequence for siRNA

```

```

<220>
<221> Target RNA Sequence
<222> (1)..(21)
<223> Target MUC1 RNA Sequence for siRNA

```

```

<400> 21 21
aaaaggagac ttcggctacc c

```

```

<210> 22
<211> 21
<212> DNA
<213> ARTIFICIAL

```

```

<220>
<223> Synthesized Sequence

```

```

<220>
<221> SEQUENCE siRNA
<222> (1)..(21)
<223> Synthesized Sequence

```

```

<400> 22 21
aaggagacuu cggcugccct t

```

```

<210> 23

```

<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 23
gggcagccga agucuccuut t 21

<210> 24
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> TARGET MUC1 SEQUENCE FOR sirNA

<400> 24
aaaggagact tcggtaccc a 21

<210> 25
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 25
aggagacuuc ggcuaacccat t 21

<210> 26
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 26
uggguagccg aagucuccut t 21

<210> 27
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> TARGET MUC1 RNA SEQUENCE FOR sirNA

<400> 27
aaggagactt cggctaccca g 21

<210> 28
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 28
ggagacuucg gcuacccagt t 21

<210> 29
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHETIC SEQUENCE

<400> 29
cuggguagcc gaagucucct t 21

<210> 30
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> TARGET MUC1 RNA SEQUENCE FOR sirNA

<400> 30
aaccagcttc aggttcagct g 21

<210> 31
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 31
ccagcuucag guucagcugt t 21

<210> 32
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 32
cagcugaacc ugaagcuggt t 21

<210> 33
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> TARGET MUC1 RNA SEQUENCE FOR sirNA

<400> 33
aacggcacct ctgccagggc t 21

<210> 34
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 34
cggcaccucu gccagggcut t 21

<210> 35
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> SYNTHESIZED SEQUENCE

<400> 35
agcccuggca gaggugccgt t 21

<210> 36
<211> 21
<212> DNA
<213> Homo Sapien

<400> 36
aagactgatg ccagtagcac t 21

<210> 37
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 37
gacugaugcc aguagcacut t 21

<210> 38
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 38
agugcuacug gcaucaguct t 21

<210> 39

<211> 21
<212> DNA
<213> Homo Sapien

<400> 39
aattgactct ggccttccga g 21

<210> 40
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 40
uugacucugg ccuuccgagt t 21

<210> 41
<211> 20
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 41
cucggaaggc cagagucatt 20

<210> 42
<211> 21
<212> DNA
<213> Homo Sapien

<400> 42
aaggtaccat caatgtccac g 21

<210> 43
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 43
gguaccauca auguccacgt t 21

<210> 44
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 44
cguggacauu gaugguacct t 21

<210> 45
<211> 21
<212> DNA
<213> Homo Sapien

<400> 45
aatgtccacg acgtgaagac a 21

<210> 46
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 46
uguccacgac gugaagacat t 21

<210> 47
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 47
ugucuucacg ucguggacat t 21

<210> 48
<211> 21
<212> DNA
<213> Homo Sapien

<400> 48
aatcagtata aaacggaggc a 21

<210> 49
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 49
ucaguauaaa acggaggcat t 21

<210> 50
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 50
ugccuccguu uuauacugat t 21

<210> 51
<211> 21
<212> DNA
<213> Homo Sapien

<400> 51
aaaacggaag cagcctctcg a 21

<210> 52
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 52
aacggaagca gccucucggt t 21

<210> 53
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 53
ucgacaggcu gcuuccguut t 21

<210> 54
<211> 21
<212> DNA
<213> Homo Sapien

<400> 54
aaacggaagc agcctctcga t 21

<210> 55
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 55
acggaagcag ccucucgaut t 21

<210> 56
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 56
aucgagaggc ugcuuccgut t 21

<210> 57
<211> 21
<212> DNA
<213> Homo Sapien

<400> 57
aacggaagca gcctctcgat a 21

<210> 58
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 58
cggaagcagc cucucgauat t 21

<210> 59
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 59
uauccgagagg cugcuuccgt t 21

<210> 60
<211> 21
<212> DNA
<213> Homo Sapien

<400> 60
aagaactacg ggcagctgga c 21

<210> 61
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 61
gaccuacggg cagcuggact t 21

<210> 62

<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 62
auccagcugc ccguaguuct t 21

<210> 63
<211> 21
<212> DNA
<213> Homo Sapien

<400> 63
aagggggttt tctgggcctc t 21

<210> 64
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 64
ggggguuuuc ugggccucut t 21

<210> 65
<211> 21
<212> DNA
<213> ARTIFICIAL

<220>
<223> Synthesized Sequence

<400> 65
agaggcccag aaaaccccct t 21

<210> 66
<211> 21
<212> DNA
<213> DNA

<400> 66
aagttcagtg cccagctcta c 21

<210> 67
<211> 21
<212> DNA
<213> Homo Sapien

<400> 67
guucagugcc cagcucuact t 21

<210> 68

<211> 21
<212> DNA
<213> Homo Sapien

<400> 68
guagagcugg gcacugaact t 21

<210> 69
<211> 21
<212> DNA
<213> Homo Sapien

<400> 69
aaggtttctg caggtaacgg t 21

<210> 70
<211> 21
<212> DNA
<213> Homo Sapien

<400> 70
gguuucugca gguaauggut t 21

<210> 71
<211> 21
<212> DNA
<213> Homo Sapien

<400> 71
accauuaccu gcagaaacct t 21

<210> 72
<211> 19
<212> DNA
<213> Homo Sapien

<400> 72
gcgcgctttg aaggattcg 19

<210> 73
<211> 21
<212> DNA
<213> Homo Sapien

<400> 73
gcgcgcuuug uaggauucgt t 21

<210> 74
<211> 21
<212> DNA
<213> Homo Sapien

<400> 74
cgaauccuac aaagcgcgct t 21

<210> 75

<211> 1424
 <212> RNA
 <213> ARTIFICIAL

<220>
 <223> Synthesized Sequence

<400> 75
 caaguuggca gaaguggcug ccacugcugg guuuguguaa gagaggcugc ugccaccauu 60
 accugcagaa accuucucau aggggcuacg aucgguacug cuaggggggca cauagcgccc 120
 augggugugg uaggugggggu acucgcucau aggaugguag guaucccggg cuggaaagau 180
 guccagcugc ccguaguucu uucggcggca cugacagaca gccaaaggcaa augagauaga 240
 caaugccagc gcaaccagaa cacagaccag caccagcagc gcgaugcccc agccuggcac 300
 cccagcccca gacuggggcag agaaaggaaa uggcacauca cucacgcuga cgucugagau 360
 cgucagguua uaucgagagg cugcuuccgu uuuauacuga uugaacugug ucuccacguc 420
 guggacauug augguaccuu cucggaaggc cagagucaau uguaccacca cagauccugg 480
 ccugaacuua auauuggaga ggcccagaaa acccccuugu uuauaaaucu gaaaaacau 540
 uucagaaaug ucucucugca gcucuuggua guagucggug cugggaucuu ccagagagga 600
 auuaaacugg agguuugaaa ugugaaaaga caggaaaaag aaagagaccc caguagacaa 660
 cuggggagaa gugcugugau uggaggaggu gagaggaggu accgugcuau ggugagugcu 720
 acuggcauca gucuuggugc uauggcuggc aaggguuggua ggagauacag agugguggu 780
 gggaaauag aauggagugc ucuugcuggc uggguugug guagcccugg cagaggugcc 840
 guugugcacc agaguagaag cugagccuga ugcagagccu gaggccgagg ugacauugug 900
 gacuggaggg gcgguggagc ccaaggcggg ccuguugucc ggggccgagg ugacaccaug 960
 ggcugggggg gcgguggagc ccggggccgg ccugguugucc ggggccgagg ugacaccgug 1020
 ggcugggggg gcgguggagc ccggggcugg cuuguugucc ggggcugagg ugacaucgug 1080
 ggcuggcggg gugguggagc ccaggcugg ccuggugacu gggaccgagg ugacauccug 1140
 ucccaggugg cagcugaacc ugaagcuggu uccguggccg gggccagagu gacauccugu 1200
 cccugagugg uggaggagcc ugaaccgggg cuguggcugg agaguacgu gcuggucaua 1260
 cucacagcau ucuucucagu agagcugggc acugaacuuc ucuggguagc cgaagucucc 1320
 uuuuccacc cuggguaga gcuugcauga ccagaaccug uaacaacugu aagcacugug 1380
 aggagcagca gcaggaagaa aggagacugg gggccggug ucau 1424

<210> 76
 <211> 40
 <212> RNA
 <213> siRNA

<400> 76

cucauagggg cuacgaucgg uacugcuagg gggcacauag 40

<210> 77
<211> 40
<212> RNA
<213> siRNA

<400> 77
cagcugcccc uaguucuuuc ggcggcacug acagacagcc 40

<210> 78
<211> 40
<212> RNA
<213> siRNA

<400> 78
agacaaugcc agcgcaacca gaacacagac cagcaccagc 40

<210> 79
<211> 40
<212> RNA
<213> siRNA

<400> 79
gccugggcacc ccagccccag acugggcaga gaaaggaaau 40

<210> 80
<211> 40
<212> RNA
<213> siRNA

<400> 80
gcugacgucu gagaucguca gguuauaucg agaggcugcu 40

<210> 81
<211> 40
<212> RNA
<213> siRNA

<400> 81
auugaacugu gucuccacgu cguggacauu gaugguaccu 40

<210> 82
<211> 40
<212> RNA
<213> siRNA

<400> 82
agucaauugu accaccacag auccuggccu gaacuuaaua 40

<210> 83
<211> 40
<212> RNA
<213> RNA

<400> 83

aaaacccccu uguuuuauaaa ucugcaaaaa cauucagaa 40

<210> 84
<211> 40
<212> RNA
<213> RNA

<400> 84
cucuugguag uagucggugc ugggaucuu cagagaggaa 40

<210> 85
<211> 40
<212> RNA
<213> RNA

<400> 85
ugaaauguga aaagacagga aaaagaaaga gaccccagua 40

<210> 86
<211> 40
<212> RNA
<213> RNA

<400> 86
agugcuguga uuggaggagg ugagaggagg uaccgugcua 40

<210> 87
<211> 40
<212> RNA
<213> RNA

<400> 87
ggcaucaguc uuggugcuau ggcuggcaag ggugguagga 40

<210> 88
<211> 40
<212> RNA
<213> RNA

<400> 88
agaggugccg uugugcacca gaguagaagc ugagccugau 40

<210> 89
<211> 40
<212> RNA
<213> RNA

<400> 89
cagggcuggc cuggugacug ggaccgaggu gacauccugu 40

<210> 90
<211> 40
<212> RNA
<213> RNA

<400> 90

cacagcauuc uucucaguag agcugggcac ugaacuucuc 40

<210> 91
<211> 40
<212> RNA
<213> RNA

<400> 91
cgcucauagg augguaggua ucccgggcug gaaagauguc 40

<210> 92
<211> 40
<212> RNA
<213> RNA

<400> 92
ucuuucggcg gcacugacag acagccaagg caaaugagau 40

<210> 93
<211> 40
<212> RNA
<213> RNA

<400> 93
caaccagaac acagaccagc accagcagcg cgaugcccca 40

<210> 94
<211> 40
<212> RNA
<213> RNA

<400> 94
ccccagacug ggcagagaaa ggaaauggca caucacucac 40

<210> 95
<211> 40
<212> RNA
<213> RNA

<400> 95
ucgucagguu auaucgagag gcugcuuccg uuuuauacug 40

<210> 96
<211> 40
<212> RNA
<213> RNA

<400> 96
ccacgucgug gacauugaug guaccuucuc ggaaggccag 40

<210> 97
<211> 40
<212> RNA
<213> RNA

<400> 97

ccacagaucc uggccugaac uuaauauugg agaggcccag 40

<210> 98
<211> 40
<212> RNA
<213> RNA

<400> 98
uauaaaucug caaaaacauu ucagaaaugu cucucugcag 40

<210> 99
<211> 40
<212> RNA
<213> RNA

<400> 99
cggugcuggg aucuuccaga gaggaauuaa acuggagguu 40

<210> 100
<211> 40
<212> RNA
<213> RNA

<400> 100
aggaggugag aggagguacc gugcuauggu gagugcuacu 40

<210> 101
<211> 40
<212> RNA
<213> RNA

<400> 101
ugcuauggcu ggcaagggug guaggaguau cagaguggug 40

<210> 102
<211> 40
<212> RNA
<213> RNA

<400> 102
gcaccagagu agaagcugag ccugaugcag agccugaggc 40

<210> 103
<211> 40
<212> RNA
<213> RNA

<400> 103
ugacuggggac cgaggugaca uccuguccca gguggcagcu 40

<210> 104
<211> 40
<212> RNA
<213> RNA

<400> 104

caguagagcu gggcacugaa cuucucuggg uagccgaagu

40

<210> 105
 <211> 164
 <212> PRT
 <213> Homo Sapien

<400> 105

Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr
 1 5 10 15

Val Leu Thr Ala Thr Thr Ala Pro Lys Pro Ala Thr Val Val Thr Gly
 20 25 30

Ser Gly His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala
 35 40 45

Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Phe Asn
 50 55 60

Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg
 65 70 75 80

Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly Gly Phe Leu
 85 90 95

Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu
 100 105 110

Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr
 115 120 125

Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr
 130 135 140

Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln
 145 150 155 160

Ser Gly Ala Gly

<210> 106
 <211> 102
 <212> PRT
 <213> Homo Sapien

<400> 106

Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu
 1 5 10 15

Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly Gly
 20 25 30

Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val
 35 40 45

Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val
 50 55 60

Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr Asn
 65 70 75 80

Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser
 85 90 95

Ala Gln Ser Gly Ala Gly
 100

<210> 107
 <211> 19
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 107

Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu
 1 5 10 15

Gln Arg Asp

<210> 108
 <211> 100
 <212> PRT
 <213> Homo Sapien

<400> 108

Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg
 1 5 10 15

Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly Gly Phe Leu
 20 25 30

Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu
 35 40 45

Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His Asp Val Glu Thr
 50 55 60

Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr
 65 70 75 80

Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln
 85 90 95

Ser Gly Ala Gly
 100

<210> 109
 <211> 20
 <212> PRT
 <213> ARTIFICIAL

<220>
 <223> SYNTHETIC SEQUENCE

<400> 109

Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val Val Gln Leu Thr Leu
 1 5 10 15

Ala Phe Arg Glu
 20

<210> 110
 <211> 56
 <212> DNA
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 110
 tcgagggtac catcaatgtc cacggagtagc tgcgtggaca ttgatggtagc cttttt .56

<210> 111
 <211> 56
 <212> DNA
 <213> ARTIFICIAL

<220>
 <223> SYNTHESIZED SEQUENCE

<400> 111
 ctagaataaag gtaccatcaa tgtccacgca gtactccgtg gacattgatg gtaccc 56

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/044160 A3

(51) International Patent Classification⁷: **A61K 48/00**,
C07H 21/04

D. [US/US]; 44 Edge Creek Dr., San Antonio, TX 78254 (US).

(21) International Application Number:
PCT/US2003/035848

(74) Agent: **HIGHLANDER, Steven, L.**; Fulbright & Jaworski, L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US).

(22) International Filing Date:
12 November 2003 (12.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/293,391 13 November 2002 (13.11.2002) US
10/447,839 29 May 2003 (29.05.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 10/293,391 (CON)
Filed on 13 November 2002 (13.11.2002)
US 10/447,839 (CON)
Filed on 29 May 2003 (29.05.2003)

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 44 Binney Street, Boston, MA 02115 (US). **ILEX PRODUCTS, INC.** [US/US]; 4545 Horizon Hill Bld., San Antonio, TX 78229-2263 (US).

Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(88) Date of publication of the international search report:
28 April 2005

(75) Inventors/Applicants (*for US only*): **KUFE, Donald, W.** [US/US]; 179 Grove Street, Wellesley, MA 02181 (US). **KHARBANDA, Surender** [US/US]; 8 Jacqueline Circle, Natick, MA 01760 (US). **WEITMAN, Steven,**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUC1 INTERFERENCE RNA COMPOSITIONS AND METHODS DERIVED THEREFROM

(57) Abstract: The present invention provides compositions and methods for inhibiting the proliferation of cancer cells and increasing the sensitivity of cancer cells to chemotherapeutic agents by downregulating MUC1 expression by interfering RNA.



WO 2004/044160 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/35848

A. CLASSIFICATION OF SUBJECT MATTER												
IPC(7) : A61K 48/00; CO7H 21/04												
US CL : 514/44; 536/24.5												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/44; 536/24.5												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	US 6,716,627 (DOBIE) 6 April 2004 (06.04.2004), see entire document.	7, 8, 14-17, 23-25, 29-32										
E,X	US 2004/0209832 A1 (MCSWIGGEN et al) 21 October 2004 (21.10.2004), see entire document, particularly SEQ ID NOS: 19 and 115.	1-6										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 21 January 2005 (21.01.2005)		Date of mailing of the international search report 25 FEB 2005										
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer Tracy Vivemore Telephone No. 571-272-1600										